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ABBREVIATIONS
1D one-dimensional 
2D two-dimensional 
AcNi acetonitrile 
APCI atmospheric pressure 
chemical ionization 
COSY correlated spectroscopy 
DAD diode-array detection 
δ chemical shift 
E2 17-β-oestradiol
ESI-MS electrospray ionisation mass 
spectroscopy 
ER oestrogen receptor 
ERE oestrogen responsive element 
EtOAc ethyl acetate 
F fermented 
GUS β-glucuronidase 
HMBC heteronuclear multiple-bond 
correlation spectroscopy 
HSQC heteronuclear single-quantum 
coherence spectroscopy 
HPLC high-performance liquid 
chromatography 
HPTLC high performance thin-layer 
chromatography 
HRESIMS high-resolution electron 
(spray) ionisation mass 
spectroscopy 
JMOD J-modulated spin-echo 
experiment 
MAC minimum active 
concentration 
MeOH methanol 
MPLC medium-pressure liquid 
chromatography 
MS mass spectroscopy 
MS/MS tandem mass spectroscopy 
½ MS  half strength Murashige & 
Skoog medium 
nF non-fermented 
NMR nuclear magnetic resonance 
NOESY nuclear Overhauser effect 
spectroscopy 
NP normal-phase 
OCC open-column 
chromatography 
pER8:GUS Arabidopsis thaliana 
transgenic plant system 
PLC preparative-layer 
chromatography 
RP reversed-phase 
RPC rotation planar 
chromatography 
TLC thin-layer chromatography 
UPLC ultra performance liquid 
chromatography 
UV ultraviolet 
VLC vacuum-liquid 
chromatography 
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1. INTRODUCTION
The Southern African flora is remarkably distinct. Considerable part of its richness lies in the 
Cape Floristic Region with a surface of 89,957 km
2
. Despite this small size, it is considered 
as one of the only six floristic kingdoms of the World, beside e.g. the vast Boreal Floristic 
Region, comprising North America, Europe, northern and central Asia, and North Africa [1]. 
The Cape Floristic Region covers less than 4% of Southern Africa, yet includes almost half of 
its species, 8550, of which 73% are endemic [2]. 
The Cape flora is exceptionally diverse and evidently the Southern African traditional 
medicine is rich, using circa 3000 medicinal plants. Cyclopia genistoides and Hoodia 
gordonii are amongst those few, about 38, Southern African indigenous species, which have 
been commercialised to some extent [3]. Since 1995, the end of the cultural and economic 
isolation of South Africa, they have also gained scientific interest, due to their 
pharmacological properties, potentially promising in conditions of great importance, such as 
obesity and menopause, affecting millions of people worldwide.  
According to WHO, 65% of the world’s population live in countries where 
overweight and obesity kills more people than underweight. Obesity has become an 
epidemic, while safe and effective pharmacotherapy is still absent [4].  
By 2030 it is projected that approximately 47 million women will go through 
menopause every year worldwide [5]. As phytoestrogens are compounds derived from plants 
that could act through at least one of the main isoforms of the oestrogen receptor, they 
potentially can be used to counterbalance the hormone deficiency in menopause. However, 
phytoestrogens are also considered to be endocrine disruptors. Hence, the evaluation of the 
oestrogen-like activity of natural compounds is important both from a safety and efficacy 
point of view [6].  
Tackling chronic diseases is high priority, taken into consideration the size of the 
affected population. Obesity and menopause are lacking safe and effective treatment; hence 
new approaches are urgently needed.  
The therapeutic potential of Cyclopia genistoides and Hoodia gordonii is notable 
based on previous pharmacological studies and their traditional use; however they have 
poorly examined pharmacology and chemistry. These facts made these two species from the 
Southern African flora perfect candidates for our investigation. 
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2. AIMS OF THE STUDY
The aim of the present work was to explore the potential of metabolites of two Southern 
African medicinal plants in the treatment of obesity and menopause. 
In order to achieve these aims, the main tasks were to: 
− investigate the mechanism of action of Hoodia gordonii that is possibly also in the 
background of reported side effects of a commercial product 
− develop analytical method for the authentication of Hoodia-based products 
− perform bioactivity-guided fractionation of C. genistoides (honeybush) in order to 
identify secondary metabolites with phytoestrogenic activity 
− isolate compounds from C. genistoides by a combination of various chromatographic 
methods (OCC, VLC, RPC, MPLC, PLC and HPLC) 
− elucidate the structures of the isolated compounds by NMR and MS methods, provide 
missing NMR data on the already-known constituents 
− compare the content of active compounds, isolated from fermented and non-
fermented honeybush tea 
− examine the effect of probiotic bacteria on flavonoid glycosides isolated from 
C. genistoides, in order to investigate the possible role of intestinal bacterial flora in 
the metabolism of flavonoid glycosides and bioavailability of aglycones of honeybush 
tea 
− determine the antiproliferative effects of phytoestrogens isolated from C. genistoides 
− evaluate the xanthine oxidase inhibitory activity of the isolated compounds of 
C. genistoides 
3. LITERATURE OVERVIEW
3.1. Botany of the Cyclopia and Hoodia genus and the investigated species 
3.1.1. The genus Hoodia and H. gordonii 
The Hoodia genus belongs to the tribe Ceropegieae of the subfamily Asclepiadoidae in the 
family Apocynaceae, order Gentianales, subclass Asteridae, class Magnoliopsida and 
division Magnoliophyta [7-9]. 
The genus Hoodia belongs to the stapeliads, formerly known as Stapeliineae, a group 
of highly succulent leafless plants with angled stem and clear sap, consisting 31 genera and 
328 species. Stapeliads form a monophyletic group, which is united by the derived character 
of fleshy flowers. Stapeliad flowers are nearly universally fly-pollinated, emitting wide range 
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of odours from mango or honey-like to dung or urine, but colouration and texture are also 
part of the deception. H. gordonii was reported to mimic the scent of omnivore/carnivore 
faeces or carcasses [7, 10]. Stapeliineae was merged into the tribe Ceropegieae belonging to 
the subfamily Asclepiadoidae, commonly known as 'milkweeds', which comprises ~2 700, 
mainly tropical and subtropical, species, belonging to 222 genera [7, 11].  
The already known 13 Hoodia species are limited to arid regions, they are found only 
in southern Africa and the south-western corner of Angola, from 13°S mainly within 100 km 
of the coast. In Namibia they occur along the western shoreline, in South Africa primarily in 
the Northern Cape. H. currorii subsp. lugardii is the only taxon reported from Botswana and 
Zimbabwe. H. gordonii covers almost the whole range of distribution of the genus, but 
avoids the winter-rainfall areas [7]. All Hoodia species are endangered and are in the CITES 
(Convention on International Trade in Endangered Species of Wild Fauna and Flora) 
Appendix II, which lists species that are not necessarily threatened now with extinction but 
may become so, unless their trade is closely controlled. 
H. gordonii (Masson) Sweet ex Decne. is a many-stemmed, leafless, perennial shrub, 
usually up to 1 m tall and 0.6 m broad, with spiny greenish cylindrical stems (0.1-1.0 m long, 
25-50 mm thick), branching from the base. The tubercles protruding, fused in lower half into 
11-17 angles along the stem, tipped with 6-12 mm spines. The flowering of H. gordonii is 
opportunistic; about a month after heavy raining, plants would be covered with flowers, 
which may vary in colour from intense purple and pale flesh-pink to yellowish, usually with 
darker venation. The 5-lobed corolla is between 50-100 mm in diameter and the lobes are 15 
mm long, but the size decreases as the flowering period advances, the largest appearing often 
first. The interior of the corolla is glabrous to finely papillate, papillae shortly setose. The 
corolla tube is usually pentagonal in outline [12-14]. 
3.1.2. The genus Cyclopia and C. genistoides 
The Cyclopia genus belongs to the tribe of Podalyrieae, subfamily of Faboideae, family of 
Fabaceae, order of Fabales, subclass of Rosidae, class of Magnoliopsida and division of 
Magnoliophyta [9, 15-17].  
The Cyclopia genus includes 23 species of endemic fynbos shrubs. They live in the 
coastal districts of the Cape Province, ranging from Cederberg Mountains (Western Cape) to 
Cape Peninsula in the south, and Port Elisabeth in Eastern Cape Province. Their habitat 
mostly sandy, acidic and infertile soils and as many Fabaceae species, they also exhibit 
nitrogen-fixing abilities. In consequence of the frequent fires in fynbos shrub lands, two 
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survival strategies have developed within Cyclopia species. Resprouters (C. intermedia, 
C. genistoides) have strongly developed underground part, capable of surviving fires and 
resprouting thereafter. Re-seeders (C. subternata), are typically destroyed by fire but 
afterwards their populations are recovered from soil-stored seeds [18]. 
Their name probably derives from either the Greek kyklos ‘circle round ring’ and ops 
‘an eye’ referring to a blotch on the standard, or according from kyklos and pous ‘foot’, 
indicating the circular base of the calyx [19, 20].  
Cyclopia plants are many branched, woody, perennial, non-climbing, smooth, broom-
like shrubs, characterized by digitately or palmately trifoliate needle-like leaves with narrow 
or board, hairless or hairy leaflets with rolled under margins. The bracts are paired and fused; 
the yellow, sweet, honey-like scented pea flowers are solitary or axillary and have a thrust-in 
calyx base [18-22]. In natuael veld, Cyclopia bushes are 1.5-3 m tall, depending on the 
species. 
Cyclopia genistoides (L.) Vent. has ribbed branches becoming terete, glabrous, or 
puberulous, nude at base but leafy above. The leaves are dense; leaflets are ovate or linear, 
subterete or open, backed with margins incompletely rolled in. The large golden yellow 
flowers are marked with red at the base of standard. Seeds are kidney shaped [21, 22]  
3.2. Chemistry of the Cyclopia and Hoodia genus and the investigated species 
3.2.1. Phytochemistry of the genus Hoodia 
A considerable portion of the secondary metabolites isolated from the subfamily 
Asclepiadoideae (Apocynaceae) has been characterized as pregnane glycosides [23-26]. The 
phytochemical studies of the genus Hoodia, which is limited to Hoodia gordonii have been 
focused on this class of compounds, since the investigation for the active compound of 
Hoodia gordonii, responsible for its claimed appetite-suppressant activity, led to the isolation 
of an oxypregnane glycoside P57AS3 (hereinafter referred to as P57). Interestingly, two 
species, members of the Asclepiadoideae subfamily have been reported with similar effects 
as H. gordonii. One of the most abundant pregnane glycosides of Cynanchum auriculatum, 
wilfoside K1N, which structure resembles to P57 and the extract of Caralluma fimbriata, rich 
in pregnane glycosides, have been described to have appetite suppressant activity [27, 28].  
Besides P57, an abundance of pregnane glycosides, comprising five aglycones, were 
identified as main constituents. Further components belonging to the compound classes of 
sterols, fatty acids, and alcohols were detected in low concentrations in the saponified 
methanolic extract of H. gordonii [29]. 
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The flower volatiles of H. gordonii were also studied, given the fact, that Hoodia 
species are stapeliads, emitting strong fetid scents in order to attract pollinators [10]. 
Pregnane glycosides 
Pregnane glycosides, containing 6-deoxy-, 2,6-dideoxy sugars (β-D-thevetose, β-D-
oleandrose, β-D-cymarose, β-D-digitoxose, 3-O-methyl-6-deoxy-D-allose) and glucose, can 
be grouped according to five aglycones: hoodigogenin A, calogenin, isoramanone, 
hoodistanal and dehidrohoodistanal. One sugar moiety is always attached to C-3, whereas the 
second moiety, if present, attached to C-20. 
Hoodigogenin A, the most common aglycone of the pregnane glycosides isolated 
from H. gordonii, is a unique pregnane derivate owing to the tigloyl functionality linked to 
position C-12 and the cis-fusion of rings C and D of the steroid skeleton [30]. 
So far 24 hoodigogenin A glycosides were described from H. gordonii, amongst them 
P57, which until recently was the only recognised anti-obesity compound in the species. P57 
was also detected in H. ruschii, H. currorri, H. parviflora, Stapelia hirsuta and Orbeanthus 
hardii [31, 32]. Among four Hoodia species, the P57 content was the highest in H. ruschii 
(0.254 mg/100 mg dried material) and the lowest in H. gordonii (0.043 mg/100 mg dried 
material) [33]. 
Owing to the parallel work of four research groups, the naming of the hoodigogenin A 
glycosides is ambiguous. P57, compound 2, hoodigoside A-K, W, gorgonoside A-I, L, 
formula 6-12 represents only 24 pregnane glycosides, because gorgonoside A, C, F, G, H and 
Formula 6 are the same as hoodigogenin A, hoodigoside C, formula 9, 10, hoodigoside E and 
P57 respectively [34-38]. 
  
P57 
Calogenin, the aglycone of thirteen pregnane glycosides, namely hoodigoside L-V, 
Y, Z, is not specific to the genus Hoodia, but is common in the subfamily [37, 39-42]. 
However, the tigloyl ester substitution at C-4 of the terminal sugar is a characteristic feature 
of calogenin glycosides derived from H. gordonii.  
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In contrast to hoodigogenin A, calogenin lacks the C-12 tigloyl ester functionality, 
and the majority of calogenin glycosides are bisdesmosides. The main steroid glycoside 
present in a CHCl3/MeOH (1:1) extract of H. gordonii was identified as hoodigoside L (2) 
[39]. 
 
Hoodigoside L 
Isoramanone glycoside, hoodigoside X is the only representative comprising this 
aglycone in the Hoodia genus so far [37]. Isoramanone skeleton is similar to that of 
hoodigogenin A, except it does not contain the tigloyl ester substitution at C-12. 
 
Hoodigoside X 
Hoodistanal and dehydrohoodistanal glycosides, hoodistanaloside A and B, 
respectively, were isolated as the first two naturally occurring glycosides of 5(6→7) abeo-
sterol aglycones [37]. In nature, 6-5-6-5 fused ring sterols are exceptionally rare, they have 
been identified only in two marine sponges (Stelletta hivasaensis, Svenzea zeai) and in 
Taiwania cryptomerioides (Taxodiaceae) [43-45]. 
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Volatiles 
In the subtribe Stapeliinae (Asclepiadoideae-Ceropegieae) approximately 400 species, among 
them the members of Hoodia genus, form sapromyiophilous flowers, emitting fetid scents, 
mimicking food sources or oviposition sites in order to attract pollinators [46]. A comparative 
floral scent analysis of 15 species from 11 genera within Stapeliinae, showed that H. gordonii 
contained the greatest amount of the identified compounds, 94 out of 149. Among the 
reported benzenoids, monoterpenoids, sesquiterpenoids, fatty acid derivates, nitrogenous 
compounds and sulphides, the compound with the highest relative amount was dimethyl 
trisulphide with 11.3%. Although, there was a considerable variation between different 
individuals [10]. 
Adulteration of Hoodia products 
As obesity reaching epidemic proportions, the demand for weight loss products, amongst 
them H. gordonii containing dietary supplements, is growing, yet the plant material is scarce, 
and the supply cannot meet this pressing demand. Therefore, adulteration of Hoodia products 
has become a major problem, which can occur by using synthetic pharmacons (e.g. 
sibutramine) as adulterants to intensify the anticipated effect, by substituting plant material 
with other botanicals or by simply omitting H. gordonii from the product [32, 33, 47-49]. The 
development of efficient and reliable analytical procedures for qualitative and quantitative 
analysis of Hoodia plant material as well as products claiming Hoodia content is crucial to 
authenticate commercial products undergoing scientific evaluation.  
In the last 8 years several methods have been published: HPLC-UV for chemical 
fingerprinting of three Hoodia species, HPLC-UV-Q-TOFMS, HPLC-ESI-TOFMS, ESI-
MS/MS, UPLC-UV-ESI-MS, HPLC-ESI-MS/MS techniques for the identification, 
characterisation or quantification of one or more pregnane glycosides in H. gordonii extracts, 
plant materials or products. HPLC-MS/MS identification was also established and validated 
for P57 in human, rat, mouse and rabbit plasma in accordance with FDA guidelines [31, 50-
53]. Simpler and faster methods for chemical fingerprinting of Hoodia species were also 
developed by the means of HPTLC [48, 49, 54]. Recently DNA barcoding for identification 
of H. gordonii was reported, which has been shown to be more accurate and sensitive to 
detect Hoodia than chemical profiling [32]. 
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3.2.2. Phytochemistry of the genus Cyclopia 
Tea derived from the leaves of Camellia sinensis in the forms of green, oolong, and black tea 
is the most consumed beverage in the world aside from water [55]. However, the popularity 
of the two South African herbal teas, rooibos (Aspalathus linearis (Burm.f.) R. Dahlgren) and 
honeybush (Cyclopia) is increasing as health beverages [56]. Green, black tea, rooibos and 
also honeybush are rich in polyphenolic compounds, but their profiles greatly differ. The 
major monomeric phenolic compounds in Camellia are flavanoles and their oxidational 
products; in Aspalathus the flavonoid aspalathin, a dihydrochalcone and its flavone 
analogues; in Cyclopia species the xanthones mangiferin and isomangiferin and the 
flavanone hesperidin [57]. These three compounds are present in all Cyclopia species 
analysed to date, but in different quantities [56]. According to Joubert et al. C. genistoides 
contains the highest concentrations of mangiferin (3.61 g/100 g) and isomangiferin (0.54 
g/100 g) and C. intermedia the highest concentration of hesperidin (1.74 g/100 g), when four 
species were compared, including C. sessiliflora and C. maculata [58]. 
Comprehensive phytochemical investigations of Cyclopia species have focused on the 
polyphenolic composition of three out of the six commercially important species, 
C. intermedia, C. subternata and C. genistoides. The aerial parts of Cyclopia species contain 
mainly flavones (luteolin, scolymoside, diosmetin), flavanones (naringenin, eriodictyol, 
hesperetin, narirutin, eriocitrin), isoflavones (formononetin, wistin, calycosin, orobol, 
afrormosin, fujikinetin, pseudobaptigen), xanthones (mangiferin, isomangiferin), 
benzophenones (iriflophenone-3-C-β-glucoside), coumestans (medicagol, flemmichapparin, 
sophoracoumestan), catechins (epigallocatechin-3-O-gallate), benzaldehyde derivates, 
phenylethanolderivates, but in contrast to Camellia sinensis, they do not contain caffeine and 
have low tannin content (proanthocyanidins, 4.34% of the hot water soluble solids of 
fermented honeybush) [56, 59-63]. The chemical uniqueness of Cyclopia is owed to the 
presence of mangiferin, hesperetin and isosakuranetin, as these compounds are absent in 
other genera of the Podalyrieae and Liparieae; and the absence of alkaloids, which 
accumulate in large amounts within the two tribes [64].  
There is a great inter- and intraspecies variation of polyphenols, resulting in different 
pharmacological properties [65]. Harvesting time, environmental conditions and fermentation 
greatly influence the phenolic content and thus the biological effects. Harvesting during 
summer, due to the higher level of stress (high temperature, water deficit, higher solar 
radiation) resulted in the highest levels of mangiferin, isomangiferin and iriflophenone-3-C-
glucoside [66]. Fermentation reduced the concentrations of total polyphenolic and individual 
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phenolic content (eriocitrin, narirutin, hesperidin, mangiferin, isomangiferin, hesperetin, 
hesperidin) in Cyclopia species, but C. genistoides was the least affected by it (77% 
retention) when compared to the other three, commercially important Cyclopia species [67-
69]. Yet, traditionally fermented plant material is used for the preparation of 
infusion/decoction. Lately non-fermented honeybush is also available on the market.  
Cyclopia genistoides 
A comprehensive phenolic profiling of the hot water extracts of fermented and non-
fermented C. genistoides by the means of HPLC-DAD-ESI-MS and MS/MS detection has 
been recently performed. Ten compounds were identified based on comparison with 
reference standards and thirty constituents were tentatively identified (e.g. 
tetrahydroxyxanthone-C-hexoside dimers, naringenin derivates, eriodyctiol glycosides, 
dihydrochalcones, glycosylated phenolic acids) [70]. 
Also recently, a fast and efficient method for the isolation of the C-glucosylated 
xanthones mangiferin and isomangiferin from C. genistoides was developed and additionally, 
two benzophenone derivatives: 3-C-β-glucosides of maclurin and iriflophenone were isolated 
together with hesperidin and luteolin [71]. 
The compounds isolated/identified until today from C. genistoides are displayed in 
(Table 1).  
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General structure Substituents Compound name Reference 
Benzophenone 
 
R1 = C-β-D-glucosyl  
R2 =H 
iriflophenone-3-
C-glucoside 
[70, 71] 
R1 = C-β-D-glucosyl  
R2 = OH 
maclurin-3-C-
glucoside 
[71] 
Xanthones 
 
R1 = H 
R2 = C-β-D-glucosyl 
mangiferin [60, 65, 67, 68, 70, 
72-74] 
R1 = C-β-D-glucosyl  
R2 = H 
isomangiferin [60, 65, 67, 68, 70, 
72-74] 
Flavanones 
 
R1 = O-rutinosyl, R2 = R3 = R4 = OH eriocitrin  [60, 65, 68, 70, 73] 
R1 = R2 = R3 = R4 = OH eriodyctiol [73] 
R1 = O-rutinosyl, R2 = R3 = OH, R4 = H narirutin [65, 67, 70] 
R1 = O-rutinosyl, R2 = OH, R3 = OCH3, R4 
= OH 
hesperidin [60, 65, 67, 70-73] 
R1 = R2 = OH, R3 = OCH3, R4 = OH hesperetin [65, 73] 
Flavones 
 
R1 = C-glucosyl, R2 = OH, R3 = C-
glucosyl, R4 = OH, R5 = H 
vicenin-2 [70] 
R1 = H, R2 = O-rutinosyl, R3 = OH, R4 = 
OCH3, R5 = OH 
diosmin [70] 
R1 = H, R2 = OH, R3 = H, R4=R5 = OH luteolin [67, 71-74] 
R1 = H, R2 = O-rutinosyl, R3 = H, 
R4 = R5 = OH 
scolymoside [60] 
Amino acids 
 
R1 = OH tyrosine [70] 
R1 = H phenylalanine [70] 
Table 1. Constituents isolated from C. genistoides 
C. genistoides has two chemotypes, the Overberg type with higher mangiferin and 
lesser isomangiferin content than the West coast type, but hesperidin was more prominent in 
the West Coast type in a study performed by Joubert et al [75]. The mangiferin content of 
both types decreased with harvesting date (p < 0.05).  
There are limited data on other, non-polyphenolic constituents of the genus. The 
volatile fraction of non-fermented and fermented C. genistoides contains numerous saturated 
and unsaturated alcohols, aldehydes, methyl ketones and terpenoids. The non-fermented plant 
material had lower relative concentration of terpenoids; 6-methyl-5-hepten-2-one was its 
major constituent (54%), while in the fermented plant material, linalool was the most 
abundant compound with 36% [76]. 
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3.3. Ethnomedicinal use of the investigated species 
3.3.1. Hoodia gordonii 
The modern World first recorded encounter with Hoodia was in 1774, when Francis Masson 
and Carl P. Thunberg gathered Hoodia pilifera and documented, that the stems of Hoodia 
pilifera were eaten by the “Hottentots” in order to suppress appetite and to quench thirst. In 
1932 a pharmacist, R. Marloth experienced these effects after consumption of H. pilifera [7, 
77]. 
Shepherds and hunters primarily of the Khoisan people of the Kalahari, consume 
Hoodia species, and they use the term ‘veldkos’ to refer to them, which means food from the 
veld [11, 77]. H. flava, H. officinalis and H. pilifera are commonly known as ‘ghaap’ and 
often consumed for their edible stems. After cutting or breaking the stems off, the spines are 
removed by rubbing them on a stone, and then the stems are cut into strips and eaten. They 
have a peculiar persistent sweet taste and are said to quench thirst and suppress appetite. 
Some species are also used for various diseases, such as H. officinalis for pulmonary 
tuberculosis and haemorrhoids, H. currori for diabetes, honey obtained from flowers of 
H. gordonii for cancer, or several Hoodia species as stomachic [7, 11, 78, 79].  
The large, hard-spined species like H. alstonii, H. currorii and H. gordonii are less 
often eaten. Hoodia gordonii, ‘bitterghaap’ in Afrikaans, is used as an appetite suppressant, 
but paradoxically, it can also be consumed in order to stimulate the appetite; and it is also 
eaten for abdominal pain, indicating peptic ulceration and tuberculosis [79, 80]. Since 
H. gordonii has a bitter taste, in some areas it is considered worthless as food or medication. 
Yet, in the Kalahari it is consumed raw or cooked, directly after good rains, which ameliorate 
the bitterness [11, 81].  
The documented use of Hoodia species as a food and water substitute in colonial 
botanical accounts led to its inclusion to a project in 1963. This research programme by CSIR 
(Council for Scientific and Industrial Research) aimed at determining the nutritional and 
possible toxic properties of edible wild plants of the region, the “foods from the veld”. As a 
result, Hoodia gordonii, in particular, P57 was patented in 1995 as an appetite-suppressant, 
which triggered scientific interest. 
3.3.2. Cyclopia genistoides 
In the 17
th
 century, Dutch colonists began to discover the local herbs of South Africa
probably from local tribes such as the Khoisan. They learned that honeybush was a pleasant 
tea, and a treatment for coughs, other respiratory conditions (expectorant), but was also used 
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as a restorative, to stimulate milk production in breast-feeding women and to alleviate 
menopausal symptoms [19, 56, 65, 82]. It used to be common practice in some rural districts 
that a kettle of honeybush tea was kept infusing on the stove ready for drinking while 
scenting the whole house [83]. The first appearance of Cyclopia in botanical literature was in 
1705; an illustration was published with the name of Genista rosmarinifolio triphyllos 
Promont, Bonae Spei. In the following years, it was cited under various synonyms, then 
eventually in 1825 it was named as Cyclopia genistoides [21].  
Honeybush is not one distinct species, and trade in the tea varies according to region 
[83]. Cyclopia genistoides is the original honeybush tea, but today other species are harvested 
commercially [20]. At present Cyclopia intermedia, subternata, genistoides and to a lesser 
extent sessiliflora are used for honeybush tea production [18].  
3.4. Pharmacology of the investigated species 
3.4.1. Hoodia gordonii 
Since obesity is reaching epidemic proportions and effective and safe treatment is lacking, 
the development of weight-loss medications is a great priority in western countries. In the 
history of anti-obesity drugs, several effective compounds were discovered and used, but 
their serious side effects – usually as a result of sympathomimetic action – made the 
risk/benefit ratio quite unfavourable. Hence, after the patent – which revealed the appetite-
suppressant activity of H. gordonii – was published, the majority of the performed in vivo 
and in vitro studies were conducted in order to enlighten its mechanism of action. Also 
pharmacokinetic properties of Hoodia were of great interest, because understanding the 
pharmacokinetic profile is fundamental for an accurate pharmacodynamic hypothesis. 
Pharmacokinetics 
P57, the primary active constituent of Hoodia gordonii was reported to have a moderate, 
47.5% bioavailability after oral administration (enriched H. gordonii extract equivalent to 25 
mg/kg P57) in mice [84]. The moderate bioavailability may be due to its degradation in 
stimulated gastric and intestinal fluids (SGF and SIF) and to efflux mechanisms, showed by 
in vitro experiments. Parallel to the degradation of P57 in SGF, its aglycone, hoodigogenin A 
appeared, highly stable in biological fluids. The transport of P57 across CaCo2 cell 
monolayers was concentration dependant, linear with time and the involvement of efflux 
mechanism via P-gp and MRP was indicated. The transport of hoodigogenin A, using the 
same model was bidirectional too, but unlike P57, its aglycone showed high intestinal 
permeability and passive transport [85, 86]. After rapid absorption, the concentration of P57 
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was the highest in the intestines, lower in the kidney and the lowest in the liver and it could 
not be detected in the brain. Following iv. administration (25 mg/kg) P57 concentration in 
tissues was much higher and detectable in the brain [84]. When P57 and hoodigogenin A 
were incubated with human liver microsomes, P57 showed high, its aglycone exhibited low 
stability against Phase-I oxidative metabolism, but inhibited (IC50 = 45 and 3 µM, 
respectively) the catalytic activity of CYP3A4. The activity of CYP 2C9 and 1A2 were also 
inhibited (IC50 = 40 and 50 µM) but only by the aglycone [85, 86]. P57 elimination was 
complete after 24 hours of the oral administration, with a half-life of 2.81 hours in mice [85]. 
Hoodigogenin A displayed high protein binding, which taken together with its extensive 
metabolism may limit the oral bioavailability. P57 also has unfavourable pharmacokinetics, 
as it proved to be unstable in stimulated gastric fluids and its absorption is bounded by efflux 
mechanisms. However, it was reported that the transport of P57 from crude extract was 
significantly higher than the transport of the pure P57, across fresh porcine buccal and 
intestinal tissue. The moderate bioavailability underlines the rationale of the traditional use of 
the plant, as it is consumed as food, in substantial quantities [87]. 
Pharmacodynamics 
Although many claims and non-reviewed data are available in several patent applications, but 
in vivo investigations in peer-reviewed articles are scarce. 
The first scientific report from the appetite suppressant activity of Hoodia was 
included in a patent application in 1995, which data was later published. Van Heerden et al. 
have reported, that H. gordonii (6.25-50 mg/kg) orally administered for three consecutive 
days has significantly decreased food intake in rats (n = 3-6/group) when compared to 
placebo. The effects were monitored for 8 days and the effect of Hoodia supplementation 
was comparable with the also effective anti-obesity drug, fenfluramin; the body mass gain 
was even lower in the Hoodia group [36]. Yet, because of the small population and short 
duration, this study cannot be considered as a definitive scientific proof. 
In 2004 MacLean and Luo reported an increase (p < 0.05) in the ATP content of the 
hypothalamus after intracerebroventricular (i.c.v.) injections of P57 (40 nM) in rats, 
maintained on hypocaloric or normal diet. A reduction in food intake by 50-60% was also 
observed in the 24 hours following the i.c.v. administration of P57 (0.4-40 nM) in rats (n = 4-
6/group), but the aglycone, hoodigogenin A had no effect. It was hypothesized, that it might 
trigger a signal of satiety and consequently suppresses appetite. In two whole cell systems, 
P57 (5 µM) failed to demonstrate the inhibition of Na/K
+
-ATPase or the binding of the 
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agonist ouabain, yet it caused a likely functional antagonism of ouabain and increased the 
ATP content in hypothalamic cultures, following 30 minutes incubation in vitro [88]. 
However, this mechanism of action was questioned based on the pharmacokinetic studies. 
P57 was undetectable in the brain after oral administration of P57 enriched methanolic 
H. gordonii extract in mice in the tested concentrations, thus the central nervous system does 
not likely to have a pivotal role in the suggested anorexigenic effect of P57 [84]. 
Peripheral targets were also proposed. P57 (0.5 mM) was reported to elicit a 
significant cholecystokinin (CCK) secretion in a rat ex vivo duodenal tissue preparations and 
in HuTu-80 human duodenal cell line, supposedly mediated via TAS2R14 bitter taste 
receptors [89]. CCK release was associated with induced satiety with rodents and in humans 
[90, 91]. 
The findings, published by Jain et al. were in accordance with these results. The 
authors concluded that H. gordonii could modulate hunger, because it altered metabolic 
responses to calorie restriction. Calorie restricted (25%) rats (n = 12/group) supplemented 
with H. gordonii extract (CH2Cl2:MeOH 1:1, 100 mg/kg) displayed a significant (p < 0.05) 
decline in the ghrelin and an increase in CCK levels, when compared to the calorie restricted 
group without supplementation [92]. This research group conducted a study in rats 
(n = 6/group) with the same extract at doses 50, 100 and 150 mg/kg body weight, given 
orally for five days. Dose-dependent reduction in food intake (12–26%) was observed at the 
two higher doses (p < 0.05) and there was an increase in liver glycogen stores, activity of 
mitochondrial CPT-1, thyroid hormones, CCK, leptin and a decrease in NPY and IGF-1 
levels. There was no change in blood glucose; and insulin levels were not affected 
significantly [93]. 
In another study, pregnane-glycosides enriched extract of H. gordonii (4-100 µg/ml) 
exhibited an inhibitory effect on forskolin-stimulated and basal steroid release (p < 0.01) of 
H295R cells in a dose-dependent manner, but it is not clear how it relates to the appetite 
suppressant activity of H. gordonii [94]. 
Recently, a G-protein coupled receptor, GPR119 was described as a potential target 
for the steroid glycosides of Hoodia. Its activation in the pancreatic β cells and intestinal L 
cells can stimulate insulin secretion and GLP-1 release - an insulin-releasing, appetite-
suppressing hormone -, respectively. This was the first study that reported gorgonoside F, not 
P57 as the active constituent. From six compounds tested, only gorgonoside F activated 
GPR119-mediated signal transduction in vitro; and also demonstrated insulinotropic effect on 
wild type isolated islets, but not on GPR119 knockout islets. In vivo gorgonosid F (200 
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mg/kg) and a Hoodia extract (1000 mg/kg) significantly improved oral glucose tolerance; 
increased insulin and GLP-1 level in the wild type, but not in the GPR119-deficient mice. 
During a one-day in vivo study both gorgonosid F (100-400 mg/kg) and a Hoodia gordonii 
extract (500-2000 mg/kg) was able to reduce the food intake in mice (n = 8/group). 
Interestingly, the extract and the compound at higher concentrations had appetite suppressive 
effect also on knockout mice but it was significantly lower than in the wild type subjects; 
implying the existence of mechanisms other than GPR119 activation [95]. 
Smith et al. also reported anti-obesity properties, but the treatment did not have any 
effect on blood glucose levels. In lean and obese rats, administered with high and low dose 
(80 and 160 mg/kg twice daily, n = 4/group) of a H. gordonii hydromethanolic extract, 
significant body mass reduction was observed, but in contrast to the lean subjects, obese rats 
responded significantly (p < 0.01) only to the higher dose of treatment. After 
supplementation (14 days) the adipose cell size decreased (p < 0.01) in both obese and lean 
subjects, which was in accordance with the previously reported decreased fat pad size by 
40% in broiler chickens treated (12 days, n = 10/group) with H. gordonii (300 mg/day) [96]. 
However, muscle atrophy and left ventricular hypertrophy were also registered in the 
treatment groups. Losses in muscle mass were greater in lean rats (35%, both doses) than in 
obese animals (20 and 30%), while ventricular hypertrophy, which can imply 
sympathomimetic activity, was present in all animals supplemented with the extract 
independent of dose [97]. 
This cardiovascular adverse effect aligns with the observations detected in humans. In 
a 15-day study, H. gordonii purified extract (2 × 1100 mg) showed no reduction in energy 
intake in healthy, overweight women (n = 25); however, blood pressure, pulse, heart rate, 
bilirubin and alkaline-phosphatase levels showed significant increases (p < 0.05) compared to 
placebo (n = 24) [98]. These side effects correspond with other weight loss medications, like 
sibutramine or amphetamine derivatives, already withdrawn from the market because of their 
serious side effects, including increased blood pressure and elevated pulse rate. 
There were other investigations performed on humans, but companies, that markets 
Hoodia products, conducted two of them; while another two, open-label observational studies 
were performed by two physicians. They administered their patients (7 and 8 patients) with 
Hoodia supplements. All four surveys reported weight–loss effect, yet only one of them, 
testing a H. parviflora product, was published in a peer-reviewed journal and the conflict of 
interest is presumable [99, 100].  
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Considering that H. gordonii is widely commercialized, safety studies were also 
conducted. A H. gordonii purified extract proved to be non-genotoxic in three independent 
assays, two in vitro, and one in vivo (mice), doses up to 400 mg/kg. Above 350 mg/kg 
clinical signs of toxicity were observed, such as swollen abdomen or increased mortality 
[101]. Prenatal developmental investigations were also performed. Both in rabbit (0, 3, 6, 12 
mg/kg, 25 days) and in mice (0, 5, 15, 50 mg/kg, 12 days) models a H. gordonii purified 
methanolic extract caused dose related reduction in feed intake and body weight gain, but in 
mice at the highest dose it also delayed foetal development; in rabbit at 16 mg/kg thickened 
stomach content was observed [102, 103].  
Activities beyond appetite-suppression were also investigated, such as the antioxidant 
and antiproliferative properties of hoodigoside A-K and P57; gastric acid reductive, 
gastroprotective and antidiabetic effect of P57 or the antidepressant-like effect of a 
commercial dried purified extract of H. gordonii [34], [104-106] 
Although in animal studies the appetite-suppressive effect of different H. gordonii 
preparations is unanimously shown, in the only clinical trial it was not proven. In conclusion, 
given the severity of the observed side effects and the lack of knowledge of the mechanisms 
of these events, further investigations are desirable. The mechanism of action of H. gordonii 
is still in dispute, but it is likely, that the observed effects are the result of a fine balance 
between different peripheral and/or central mechanisms, caused by several compounds. 
3.4.2. Cyclopia genistoides 
There have been no clinical trials performed with any of the Cyclopia species yet; only pre-
clinical data are available. According to the in vivo, ex vivo and in vitro laboratory 
experiments, the different extracts of Cyclopia spp. possess pleiotrop effects 
(antimutagenic/chemopreventive, phytoestrogenic and antioxidant). Based on these studies, 
the investigated effects are most likely due to the polyphenolic content of honeybush. The 
exhibited pharmacological effects had intra- and interspecies variation, possibly because of 
quantitative variation of chemical composition within and between species [56, 57, 67, 107-
113]. 
In many cases fermentation could reduce the observed effects of Cyclopia spp., but 
not that of C. genistoides in case of phytoestrogenic and antioxidant activity [56, 65, 67, 
114]. A systematic review of all of these studies will not be attempted here; rather a selection 
with emphasis on studies investigating the phytoestrogenic effect of Cyclopia species. 
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Phytoestrogens (plant-derived non-steroidal, polyphenolic secondary metabolites with 
structural and functional similarity to oestrogen) might serve as viable alternatives for 
hormone replacement therapy (HRT), given their differentiated effect on α and β oestrogen 
receptors (ER). They may be able to bind to both ER subtypes, acting as either agonist or 
antagonist, but unlike 17β-oestradiol (E2) they generally bind to the ER with a much lower 
affinity, yet have a higher affinity for ER-β than for ER-α, which is believed to protect 
against excessive cell proliferation mediated by ER-α [115, 116]. Furthermore, 
phytoestrogens may be beneficial to alleviate menopausal symptoms and to protect 
postmenopausal women against cardiovascular diseases and osteoporosis, without the risks 
associated with HRT [117, 118]. 
HRT, using conjugated equine oestrogen alone (CEE) or in combination with 
progestin (CEE + P), proved to lack overall benefit in chronic disease prevention 
(osteoporosis, heart disease) and menopausal symptom alleviation, due to increased risks of 
stroke (CEE and CEE + P), coronary heart disease, venous thromboembolic disease and 
breast cancer (CEE + P) [119, 120]. Alternative solutions, such as selective oestrogen 
receptor modulators (raloxifene and tamoxifen) have also been questioned because of their 
side-effects, such as the stimulation of endometrial growth, the occurrence of hot flashes and 
an increased risk of venous thromboembolism [121-126]. 
However, despite several promising studies, phytoestrogen treatment seems to be less 
effective than traditional HRT, and the effect of phytoestrogens on menopausal symptoms, 
such as hot flushes, is inconclusive [127, 128]. Yet, the risks of HRT and the increasing 
popularity of natural products give a rationale to the investigations seeking phytoestrogens 
with selective affinity on ERs.  
Phytoestrogenic activity 
Initial screening for phytoestrogenicity has focused on in vitro oestrogen receptor binding of 
water and methanol extracts (1.5 μg/ml) of three harvestings of four Cyclopia species 
(sessiliflora, subternata, intemerdia, genistoides). C. subternata and genistoides displayed 
significant (p < 0.01) phytoestrogenic activity and methanol extracts from non-fermented 
plant material generally displayed greater activity. Interestingly, fermentation did not affect 
the ER binding of C. genistoides, but C. subternata. A great variation of ER binding within 
species has also been reported. Depending on harvestings tested C. genistoides binded to 
hERβ, either subtypes or neither. C. genistoides (methanolic extract) demonstrated the 
strongest oestrogen receptor binding with the highest consistency to hERβ amongst the 
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species tested [65]. In a later study it was shown by the means of different assays (ERα/β 
binding, transactivation of an ERE-containing promoter reporter, proliferation of MCF-7-
BUS and MDA-MB-231 breast cancer cells and binding to SHBG), that C. genistoides 
methanol extracts (three different harvestings were tested) displayed phytoestrogenic activity 
and acted predominantly via ERβ (transactivated only through ERβ despite binding to both 
subtypes). HPLC-MS analysis suggested that the observed phytoestrogenic activity cannot 
only be ascribed to polyphenols known to be present in Cyclopia spp. [65, 72]. Mfenyana et 
al. reported positive correlation between luteolin content and efficacy and between an 
unknown flavanone and potency of C. genistoides and subternata extracts according to 
alkaline phosphatase assay and E-screen, respectively. The cup-of-tea extracts from these 
species did not only displayed oestrogenic activity, but had comparable efficacy and potency 
to commercial products containing soy isoflavones, black cohosh or red clover [73]. In an 
exhaustive investigation, C. subternata and C. genistoides extracts displayed ERα 
antagonism and ERβ agonism when expressed separately, but when co-expressed only 
agonism was observed. Breast cancer cell proliferation assays indicated that extracts 
antagonized cell proliferation in the presence of oestrogen, at lower concentrations than that 
required for proliferation. Also, lack of uterine growth and delayed vaginal opening were 
reported in immature rat uterothropic model (2000 mg/kg C. subternata extracts/day, 
n = 10/group), implying ERα antagonism, supporting the potential of Cyclopia extracts as a 
source of oestrogen analogous with a reduced risk profile [74]. 
Cyclopia extracts from specific harvestings seem promising, but blanket claim for 
their oestrogenicity cannot be made, as the observed oestrogenic potency has great inter- and 
intraspecies variability [65, 72-74]. Moreover, in a recent study, the activity guided 
fractionation of an extract from C. subternata, which displayed three desirable oestrogenic 
attributes (ERα antagonism, ERβ agonism, antagonism of E2-induced breast cancer cell 
proliferation) showed, that the retention of all these attributes in one fraction is not an 
attainable goal [63]. 
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4. MATERIALS AND METHODS
4.1. Plant material 
The aerial parts of Hoodia gordonii were obtained from a local succulent plant nursery 
(707.7 g) in 2013 January Szeged, Hungary, and authenticated by the author (O. Roza). 
Fermented and non-fermented Cyclopia genistoides (L.) Vent. (1.7 and 1.3 kg, 
respectively) were a gift from Van Zyl and Mona Joubert owners of Agulhas Honeybush Tea, 
from their farm near Bredasdorp in South Africa. Botanical identifications were performed 
by Dr. Hannes de Lange, an expert in taxonomy and commercializing of honeybush. 
Fermentation was carried out according to the traditional method for this material [129].  
The plant materials of C. genistoides were stored at room temperature until preparation, 
while the aerial parts of H. gordonii were freshly grounded and extracted. Voucher 
specimens (no. 812 - H. gordonii, 825 - F C. genistoides and 826 - nF C. genistoides, 
respectively) have been deposited at the herbarium of the Department of Pharmacognosy, 
University of Szeged, Szeged, Hungary. 
Fytofontana Dietceutical Hoodia spray (distributed by Herb-Pharma Hu Ltd., Budapest, 
Hungary), a medical device registered in Hungary, was bought in a local pharmacy in 
Szeged, Hungary. The composition of the product displayed on the package is the following: 
Hoodia gordonii extract (corresponding to 2.2 g plant material /2 ml solution), peppermint, 
alcohol. 
The commercial probiotic bacteria mixture ProBio 6 capsule (Béres Pharmaceuticals Ltd., 
Budapest, Hungary) is claimed to contain 5 billion bacteria (Lactobacillus helveticus, 
Lactococcus lactis, Lactobacillus rhamnosus, Bifidobacterium longum, Bifidobacterium 
breve, Bifidobacterium bifidum) per 515 mg. 
4.2. Extraction of plant materials  
The extract of authentic H. gordonii for HPLC and HPTLC analyses was prepared from 7 g 
fresh, ground plant material with 3 × 25 ml of AcNi, using ultrasonic bath (15 min). After 
filtration, the solution was evaporated to dryness under reduced pressure. The residue was 
dissolved in 2 ml of MeOH, filtered and then evaluated. 
Twenty-five ml of Hoodia spray was evaporated to dryness, and then the residue was 
dissolved to the original volume with physiological saline-DMSO (95:5), and after filtered to 
perform the organ baths studies. The Hoodia spray itself was used for TLC, MS, HPLC and 
HPTLC analyses. 
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The dried fermented and non-fermented herbs of C. genistoides were extracted via 
ultrasonication with methanol (12 l and 10 l) at room temperature for 30 minutes. The extract 
was concentrated in vacuo and then diluted with H2O, and liquid-liquid partition was 
performed (5 × 500 ml), affording n-hexane, dichloromethane, ethyl-acetate, the remnant 
aqueous layers and insoluble part. 
The aqueous “cup of tea” extracts were prepared for the HPLC quantitative determination. 
5 g plant material was extracted with 100 ml boiling tap water for 10 minutes. For 
comparison a methanolic extract was also prepared (10 ml MeOH + 1 g plant material, 10 
minutes, ultrasonication). 
Aqueous extracts of the fermented and non-fermented honeybush tea were prepared for 
the testing of bacterial fermentation by adding freshly boiled tap water to the dried plant 
material (200 ml boiling tap water + 10 g drug). The teas were allowed to steep for 30 
minutes at room temperature, and then filtered. After lyophilisation, 200 mg of the dry 
residues were dissolved in 10 g DMSO and 189.98 g of 37 °C physiologic saline solution and 
3 g ProBio 6 was added to each solution. Blank experiments were also performed, which did 
not contain the probiotic bacteria. The mixtures were gently mixed at 37 °C for 50 hours. 
After lyophilisation of the mixtures, they were re-dissolved in 5 ml MeOH and filtered 
through 0.45 μm syringe filter (Labex Ltd., FilterBio®, PTFE-L syringe filter). Measurements 
were carried out in triplicate, luteolin and naringenin contents were also measured in the teas 
before bacterial fermentation. Luteolin and naringenin were used as standards, previously 
isolated in our lab (wavelength of detection 348 nm and 288 nm, respectively) [130]. 
4.3. Comparison of the Hoodia product with authentic plant material and 
investigation of its falsification 
HPLC: HPLC was carried out on a Kinetex XB-C18 (2.6 µm, 100 Å, 100 × 4.6 mm) column 
(Phenomenex, Torrance, USA), operated at 40 C, using: 
Instrument 1: Waters Alliance 2695 separations module with Empower software 
(Waters Associates, Milford, MA), Waters 600 controller and pump, 
2487 dual absorbance detector  
Method 1:  Injection volume of 20 µl, gradient solvent system consisting 
methanol, acetonitrile and H2O, was according to the method Janssen 
et al. [51]. 
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TLC: thin layer chromatographic analyses were carried out on aluminium sheets (20 × 20 
cm), coated with silica gel 60 F254 (Merck KgaA, Darmstadt, Germany). For each test 10 µl 
of Hoodia spray and standard solutions were applied.  
Mobile phases, visualisation:   
TLC-A: MeOH (95:5), Dragendorff reagent 
TLC-B: MeOH - cc. NH3 (100:1.5), Marquis reagent (cc. H2SO4 - formalin 
20:1.5), heating at 110 °C for 2 minutes, detection under UV light (366 
nm) [131] 
TLC-C: CH2Cl2 - cc. NH3 - 2-propanol (5:15:80), ninhydrin reagent, heating at 
110 °C for 5 minutes 
HPTLC: HPTLC comparison of the product and authentic H. gordonii extract was carried out 
according to the method described by Rumalla et al., using silica gel coated 60 F254 plates 
(10 × 20 cm) (Merck KgaA, Darmstadt, Germany) [48].  
Mobile phases, visualisation: 
HPTLC-D: CHCl3 - MeOH - H2O (70:30:3), anisaldehyde, heating at 110 °C for 5 
minutes 
Mass spectrometry: analyses were performed on an API 2000 triple quadrupole tandem mass 
spectrometer (AB Sciex Instruments, Foster, CA.). Data integration was performed with 
Analyst 1.5.2 software version (AB Sciex Instruments). Electrospray ionisation interface was 
used with a source temperature of 250 °C, operating in positive mode using multiple reaction 
monitoring (MRM). The following conditions were used: capillary voltage 5500, curtain gas 
pressure 10 psi, collusion gas pressure 6 psi, nebulizer gas pressure 50 psi and auxiliary gas 
pressure 20 psi. 
4.4. In vitro organ bath studies 
Uteri were removed from non-pregnant rats in the oestrus phase and from pregnant rats on 
day 22 of gestation. The tension of the myometrial rings was measured with a gauge 
transducer (SG-02; Experimetria Ltd., Budapest, Hungary) and recorded with SPEL 
Advanced ISOSYS Data Acquisition System (Experimetria Ltd., Budapest, Hungary) [132]. 
The uterus-relaxant effect of Hoodia spray was investigated on spontaneous and 25 mM KCl-
induced contractions alone and in the presence of 10 µM propranolol. All experiments were 
carried out on at least 6 animals (female Sprague-Dawley rats). Unpaired t-test was used for 
statistical evaluation of the presence of propranolol. All calculations and statistical analyses 
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were performed with Prism 5.0 computer software (Graph Pad Software Inc, San Diego, CA, 
USA). For further details please see Appendix I. 
4.5. Isolation, purification and quantification of compounds from C. genistoides 
Open-column chromatography: OCC was performed on polyamide for column 
chromatography (ICN), on silica gel (160–200 mesh, Qingdao Marine Chemical Co., 
Qingdao, China) and on Sephadex LH-20 (Sigma). The extracts, after dissolution, were 
adsorbed on stationary phase, corresponding to double the amount of their dried weight. 
After drying, the yielded powders were placed on the stationary phase (fourfold amount of 
the powder).  
OCC-P: eluent: mixtures of MeOH - H2O (2:3, 3:2, 4:1, 1:0); volume of collected 
fractions: 100 ml; sorbent: polyamide  
OCC-NP-1: eluent: n-hexane - acetone (2:1 to 0:1); volume of collected fractions: 
20 ml; sorbent: silica gel  
OCC-NP-2: eluent: n-hexane - acetone (3:1 to 0:1); volume of collected fractions: 
20 ml; sorbent: silica gel  
OCC-NP-3: eluent: n-hexane - acetone (5:1 to 0:1); volume of collected fractions: 
20 ml; sorbent: silica gel  
OCC-Sph: eluent: methanol; volume of collected fractions: 1 ml; sorbent: Sephadex 
LH-20 
Vacuum-liquid chromatography: The extracts, after dissolution, were adsorbed on silica gel 
60 GF254 (15 µm, Merck), corresponding to double the amount of their dried weight. After 
drying, the yielded powders were placed on the stationary phase (fourfold amount of the 
powder) in a filter funnel. The VLC columns were developed under gentle vacuum, provided 
by a water pump. 
VLC-NP: eluent: stepwise gradient, EtOAc - MeOH (1:0 to 0:1); volume of collected 
fractions: 30 ml; sorbent: silica gel  
Rotation planar chromatography: RPC was carried on a Harrison Model 8924 Chromatotron 
instrument (Harrison Research). The stationary phase for RPC was silica gel 60 GF254 
(Merck), manually coated on the rotor as a 1 or 2 or 4 mm layer. The flow rates were 4 to 8 
ml/min. The separation was achieved with gradient elution in 5 or 6 steps with cyclohexane - 
acetone (1:0 to 0:1). This method is herein after referred to as RPC-NP. 
Preparative layer chromatography: PLC was performed on 10 × 20 cm silica plates (silica 
gel 60 F254, Merck and 60 RP-18 F254s). The plates were developed by an ascending 
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technique in a glass chamber at room temperature. Separation was monitored in UV light at 
254 nm. Compounds were eluted from the scraped adsorbent with CHCl3 - MeOH (5:1). 
Mobile phases: PLC-E: MeOH - H2O (4:6) 
PLC-F: EtOAc - MeOH - H2O (100:16:14) 
PLC-G: Acetone - n-hexane (1:2) 
PLC-H: CH2Cl2 - MeOH (10:0.15) 
HPLC: The following instruments and methods were used: 
Instrument 1: Waters Alliance 2695 separations module with Empower software 
(Waters Associates, Milford, MA), Waters 600 controller and pump, 
2487 dual absorbance detector 
Instrument 2: Waters Alliance 2695 separations module with Empower software 
(Waters Associates, Milford, MA), Waters 600 controller and pump, 
Waters Photodiode Array Detector 2998 (190–800 nm), Injector 
Rheodine 7725i 
Instrument 3: two JASCO PU-2080 HPLC pumps, JASCO MD-2010 Plus multi-
wavelength detector (JASCO Inc., Tokyo, Japan) 
Instrument 4: dual Shimadzu LC-10AT pumps, Shimadzu SPD-10A UV-vis detector 
Method 2: eluent: gradient solvent system consisting of MeOH and acidified 
(0.1% H3PO4) water; flow rate: 1 ml/min; column: Kinetex C18 (5μm, 
100 Å, 150 × 4.6 mm) column (Phenomenex, Torrance, USA), 
operated at 20 °C. Injection volume was 20 μl. The gradient consisted 
of three steps: for 21 minutes the % of the acified water decreased from 
80% to 24% then in one minute it reached 80 % again then for six 
minutes this ratio was maintained. 
Method 3: eluent: MeOH - H2O, (3:2); flow rate 2 ml/min; column: Hibar 
Purospher STAR RP-18e (5 μm, 250 × 10.0 mm) semipreparative 
column (Merck KGaA, Darmstadt, Germany) 
Method 4:  eluent: n-hexane - CH2Cl2 - MeOH (4:8:0.015); flow rate: 2 ml/min; 
column: Luna CN (5 μm, 250 × 10.0 mm) semipreparative column 
(Phenomenex Inc., Torrance, USA) 
Method 5: eluent: AcNi - H2O (3.5:10); flow rate 0.75 ml/min; column: 
LiChroCART RP-18e (5 μm, 250 × 4 mm) 
Chromatographic separations were monitored at a wavelength range of 190-400 nm.  
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Medium-performance liquid chromatography: MPLC was performed by a Büchi apparatus 
(Büchi Labortechnik AG, Flawil) using a 40 × 150 mm RP18ec column (40-63 μm, Büchi). 
MPLC-1: EtOAc - MeOH - H2O (20:1:1 to 0:1:0); flow rate: 18 ml/min 
MPLC-2: MeOH - H2O (2:8 to 1:0); flow rate: 35 ml/min 
4.6. Characterisation and structure determination of the isolated compounds 
1
H-NMR (500 MHz), 
13
C-NMR (125 MHz) and 2D NMR were recorded in CD3OD or 
CDCl3 or DMSO using a Bruker Avance DRX 500 spectrometer or a JEOL ECS 400 MHz 
FT-NMR spectrometer and chemical shifts were given in δ (ppm) value relative to 
tetramethylsilane (TMS) as internal standard. The signals of the deuterated solvents were 
taken as reference. Two-dimensional (2D) experiments were performed with standard Bruker 
software. In the COSY, HSQC and HMBC experiments, gradient-enhanced versions were 
used. 
MS spectra were recorded on an API 2000 Triple Quad mass spectrometer with APCI or ESI 
ion source using positive or negative of polarity.  
The HRESIMS data were recorded, on a Shimadzu IT-TOF spectrometer, equipped with 
electrospray source. 
4.7. Oestrogen-like reporter assay 
pER8:GUS seeds were grown in the dark for 24-36 hours at 4 °C on medium (½ MS, 1% 
sucrose, 0.8% phytoagar) for vernalisation and then germinated under white light for 
72 hours at 24 °C. The plants were transferred to a 24-well microtiter plate in the presence or 
absence of test samples and incubated at 24 °C for 48 hours. Transgenic plants (3-5) were 
added to each well, in order to evaluate oestrogenic activity. Plants cultured with 0.31-10 nM 
E2 were taken as a positive control.  
4.8. Histochemical assay 
After incubation in the presence or absence of test samples, transgenic plants were soaked in 
0.2 ml per well of the GUS assay solution [50 mM Na3PO4 buffer (pH 7.0), 10 mM EDTA 
(pH 8.0), 2 mM X-Gluc, 0.5 mM K3Fe(CN)6, 0.5 mM K4Fe(CN)6, and 0.1% Triton X-100] in 
a 24-well plate and incubated for 3 hours or overnight at 37 °C. After washing, 70% aqueous 
EtOH was used to remove chlorophyll. Using a ZEISS Axiovert 200 inverse microscope, 
samples were examined for GUS staining and photographed with a digital camera. The 
minimum active concentration (MAC) of each sample was recorded upon the disappearance 
of the insoluble blue dye (5,5'-dibromo-4,4'-dichloro-indigo). The last concentration in the 
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series, where the blue colour was still detectable was considered the minimum active 
concentration. The parallel experiments were in accordance, hence no SEM/SD were 
calculated.  
4.9. Antiproliferative assay 
The antiproliferative properties of the prepared extracts and natural products were determined 
on A2780 and T47D cancer cell lines (isolated from ovarian and breast carcinoma, 
respectively; purchased from ECACC, Salisbury, UK) by means of the MTT assay [133]. All 
in vitro experiments were carried out on 2 microplates (96-well) with at least 5 parallel wells. 
Stock solutions of 10 mg/ml of the tested materials were prepared with DMSO, the highest 
DMSO content of the medium (0.3%) did not have any substantial effect on the cell 
proliferation. Cisplatin was used as reference agent which inhibited the proliferation of 
A2780 and T47D cells with IC50 values of 1.30 and 9.78 µM, respectively. 
Statistical evaluation of the results was performed by one-way analysis of variance followed 
by Dunnett posttest, using GraphPad Prism 4 (GraphPad Software San Diego, CA, USA). For 
further details please see Appendix II.  
4.10. Xanthine oxidase inhibitor assay 
Inhibition of xanthine oxidase activity was measured using the protocol recommended by 
Sigma-Aldrich, re-adapted to an assay volume of 300 µl, and published in detail before [134, 
135]. Briefly, the enzyme activity at pH 7.5 was determined by the production of uric acid 
from xanthine. Uric acid was measured at 290 nm for 3 minutes in 96-well plate, using the 
plate reader FluoSTAR OPTIMA (BMG LABTECH, Germany). The enzyme inhibitory 
effect was determined by the decreased production of uric acid. Xanthine oxidase (XO), 
isolated from bovine milk (lyophilized powder), and xanthine powder were purchased from 
Sigma-Aldrich. Allopurinol (Sigma-Aldrich, ≥99%), a well-known inhibitor of XO was used 
as positive control. Each compound or fraction was dissolved in DMSO. The final 
concentration of DMSO in the assay did not exceed 3.3% of the total volume. After the 
addition of all other reagents, the reaction was initiated by automatic addition of XO solution. 
All XO activity measurements were made in triplicate. 
Fifty percent inhibitory concentrations (IC50) were calculated using non-linear regression 
curve fitting of log(inhibitor) vs. normalized response of GraphPad Prism 5.04 software 
(GraphPad Software Inc., La Jolla, CA, USA).  
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5. RESULTS 
5.1. Sympathomimetic activity of a Hoodia product 
The only available human clinical study on Hoodia gordonii reported no change in body 
weight or energy expenditure; however, administration of a purified H. gordonii extract was 
associated with significant increase in blood pressure and pulse rate [18]. Similar side effects 
have been reported to the Department of Pharmacognosy, University of Szeged, by 
consumers of a product available on the Hungarian market (Hoodia spray). As a first step, the 
comparison of the product with authenthic plant material was performed alongside with 
testing for possible adulterants with potential for causing cardiovascular side effects (e.g. 
sibutramine, amphetamine). Then the effect of the Hoodia spray on β-adrenergic receptors in 
rat uterus was measured to explore the potential role of β-adrenergic receptor agonist activity 
in the possible cardiovascular adverse effects of the plant.  
5.1.1. Comparison of the Hoodia product with authentic plant material and 
investigation of its falsification 
First, the Hoodia spray was tested for the presence of P57 by mass spectrometry in multiple 
reaction monitoring (MRM) mode. In our experiments, P57, a characteristic compound 
of Hoodia species, was chosen for mass spectrometric identification. LiCl3 was added to the 
sample, to enhance sensitivity. Both m/z 311.3 and m/z 785.5 product ions were detected with 
the precursor ion m/z 885.5, indicating that P57 is present in the Hoodia spray. The aglycone 
was identified too, with the product ions of m/z 319.3 and m/z 337.3. All of these transitions 
have been reported in the literature for P57 [27]. 
The HPLC chromatogram of the plant extract and the product showed similarity 
(Instrument 1, Method 1), having similar fingerprints between 16 and 36 minutes at 220 nm 
(Figure 1A). Differences in peak heights and areas can be explained with the dissimilarity of 
extraction methods (in the product’s leaflet there was no reference to the extraction method 
applied). In the chromatogram of the product, few other peaks occurred, possibly due to 
additives present in the spray, such as Mentha piperita. 
Regarding the colours and retention factors of the detected spots, HPTLC analysis 
(HPTLC-D) also confirmed the similarity of the product and the plant extract. On Figure 1B 
the HPTLC chromatograms of the Hoodia spray and H. gordonii extract can be seen, together 
with the HPTLC chromatograms of four Hoodia species found in literature, using the same 
eluent system [48]. As other Hoodia species can contain several of the same constituents, but 
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in different ratios, the chance that Hoodia species other than H. gordonii being used in the 
preparation cannot be excluded [25]. 
Using TLC comparison with reference standards, sibutramine (TLC-A), amphetamine, 
methamphetamine (TLC-B) and ephedrine (TLC-C), were not detected in the product. 
 
Figure 1. A HPLC fingerprint chromatograms of Hoodia extract (blue) and Hoodia spray (black) 
B HPTLC fingerprint chromatograms of different Hoodia species, Hoodia spray and extract 
5.1.2. Beta-adrenergic receptor agonist activity 
β-adrenergic receptor agonists are reported to decrease food intake and exhibit anorectic 
properties [28]. Stimulation of β-adrenoceptors also results in different cardiovascular 
symptoms. Since cardiovascular side effects have been reported for a H. gordonii extract, the 
stimulation of β-adrenergic receptors seemed to be a rational explanation for the mechanism 
of its anorectic action [18]. Both α- and β-adrenergic receptors play crucial roles in the motor 
activity of myometrial smooth muscle, eliciting contraction and relaxation, respectively; 
rendering uterine preparations ideal for investigations of drugs with actions on the 
sympathetic system. In the presented set of in vitro organ bath experiments, the myometrial 
effects of the H. gordonii extract-containing product were monitored against spontaneous and 
KCl-stimulated contractions of uterine rings from nonpregnant and late-pregnant (day 22) 
rats; the extraction and sample preparation were carried out as described in section 4.2. In 
order to separate the actions mediated through α- and β-adrenoceptors all experiments were 
performed with and without nonselective β-antagonist propranolol (10 μM). The product 
elicited a marked and concentration-dependent relaxation against both spontaneous and 
stimulated contractions. The inhibition of spontaneous contractility was significantly 
decreased in the presence of propranolol (Figure 2). The relaxation of KCl-stimulated uteri 
was not modified in the presence of propranolol. The relaxing effect of the spray was 
substantially less pronounced on uteri from late-pregnant animals, but propranolol 
significantly modified it. 
gordonii currorii spray extract ruschii parviflora 
A B 
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Figure 2. Effects of Hoodia spray on spontaneous ((a) and (c)) and KCl-stimulated ((b) and (d)) contractility of uterine rings 
from nonpregnant ((a) and (b)) and late-pregnant ((c) and (d)) animals. Experiments were performed in the presence (■) and 
absence (□) of propranolol. *, **, and *** indicate p < 0.05, p < 0.01, and p < 0.001, respectively. 
5.2. Flavonoids from C. genistoides 
5.2.1. Isolation of compounds 
The dried fermented and non-fermented plant materials (1.7 and 1.3 kg, respectively) were 
extracted via ultrasonication with methanol (12 l and 10 l) at room temperature. The solvent 
was evaporated under reduced pressure to yield 228.2 g and 237.6 g of crude MeOH extracts, 
respectively. These extracts were subjected to solvent-solvent partition, affording n-hexane 
(F-15.7 g, nF-13.2 g), dichloromethane (F-14.8 g, nF-6.4 g), ethyl-acetate (F-29.7 g, nF-
23.35 g), the remnant aqueous layers (F-128.7 g, nF-121.4 g) and insoluble part. 
The 
1
H NMR spectra of the EtOAc layers from the non-fermented and fermented 
C genistoides were similar, thus only the EtOAc layer (23.35 g) from the non-fermented drug 
was further examined. It was subjected to VLC (VLC-NP), using a stepwise gradient of 
EtOAc - MeOH affording twelve combined fractions (V1-V12), after TLC monitoring. 
Fraction V3 was crystallised with CHCl3 - MeOH to yield CG1. 
Fraction V7 was separated by MPLC-1 with EtOAc - MeOH - H2O to give 21 
subfractions (M1-M21). Among these subfractions, M5 and M6 were subjected to further 
chromatography. Fractions M6 (777.5 mg) and M5 (65.5 mg) were separated into twelve 
(M6/1-12) and six (M5/1-6) subfractions by MPLC-2, using mixtures of MeOH - H2O. 
Subfractions M5/2 (11.2 mg) and M6/11 (21.5 mg) were purified by reverse-phase 
preparative TLC (PLC-E) to provide CG2 (1.8 mg) and CG3 (4 mg), respectively. 
a) b) 
c) d) 
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Subfraction M6/4 (55.3 mg) was further purified by normal-phase preparative TLC (PLC-F) 
and finally by gel filtration chromatography (OCC-Sph) to provide CG4 (3.3 mg). 
 
Figure 3. Isolation of compounds from C. genistoides 
The concentrated CH2Cl2 phases (F-14.8 g, nF-6.4 g) were chromatographed on a 
polyamide column (OCC-P) with mixtures of MeOH and H2O as eluents. The OCC-P 
fractions were combined into 14 (F: P1-P14) and 12 fractions (nF: PP1-PP12) according to 
the TLC monitoring (Figure 3). 
Fraction PP8 (136.8 mg) was separated on RPC-NP, eluted with a gradient system of 
cyclohexane - acetone. The RPC-NP fractions were combined after TLC monitoring into 14 
fractions (OO1-OO14). Subfraction OO14 (8.9 mg) was further purified by gel filtration 
chromatography (OCC-Sph) to provide CG1 (5.6 mg), isolated previously from the EtOAc 
phase of the non-fermented plant material. 
Fraction P3 (570 mg) was chromatographed by RPC-NP, using a gradient system of 
cyclohexane - acetone. The RPC-NP fractions were combined into 15 fractions (N1-N15). 
Then subfraction N4 (38.5 mg) was separated on normal phase HPLC (Method 4, 
Instrument 4), to yield CG5 (2.3 mg) and CG6 (2.8 mg). 
Fraction P7 (300 mg) was also subjected to RPC-NP, using the same gradient system to 
yield seventeen subfractions (O1-O17), from which O6 (11 mg) was further separated by 
normal-phase HPLC (Method 4, Instrument 4) to provide CG7 (1.7 mg) and CG8 (1.8 mg), 
whereas the crystallisation of O9 with CHCl3-MeOH provided CG9 (7.6 mg). 
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Fraction P8 (750 mg) was separated on OCC-NP-3 with an n-hexane - acetone gradient 
system to yield twenty-two subfractions (Q1-Q22). The combined subfractions Q8 + 9 and 
Q14 were chromatographed by reverse-phase HPLC (Method 5, Instrument 1) to provide 
CG10 (1.45 mg) and CG11 (1.7 mg), respectively. Crystallisation of Q13 with CHCl3-
MeOH provided CG12 (16.2 mg).  
Fraction P9 (1.68 g) was chromatographed by RPC-NP with a gradient system of 
cyclohexane - acetone to give seven subfractions (T1-T7). Subfraction T4 and T5 (410 mg, 
250 mg, respectively) were subjected to OCC-NP-1 and OCC-NP-3, respectively, to yield 
eleven (C1-C11) and eight (CD1-CD8) subfractions, respectively. C3 and CD5 were further 
purified by preparative TLC (PLC-G) to provide CG13 (16.8 mg) and CG14 (7.4 mg), 
respectively.  
Fraction P10 (475.5 mg) was subjected to silica gel CC, eluted with n-hexane – acetone 
(OCC-NP-2) to yield thirteen (CE1-CE13) subfractions. CE8 (7.5 mg) was purified by 
preparative TLC (PLC-H) to yield CG15 (1.4 mg). CE8 was also purified alongside with 
CE10 (5.1 mg) by RP-HPLC with Method 3 on Instrument 3 and with Method 5 on 
Instrument 1, respectively, to provide CG16 (1.65 mg) and CG17 (1.6 mg), respectively.  
Fraction P11 (245 mg) was chromatographed by RPC-NP and eluted with cyclohexane - 
acetone to give fifteen subfractions. Subfraction 11 (S11) was further purified by gel 
filtration chromatography (OCC-Sph) to provide CG1 (5.6 mg), isolated previously from the 
non-fermented plant material. 
5.2.2. Characterisation and structure elucidation of the isolated compounds 
The structures of the isolated compounds were determined by means of spectroscopic 
methods. High-resolution mass spectrometric measurements allowed the determination of the 
exact molecular weight and molecular composition of the compounds. The most useful 
methods in the structure elucidation were 1D and 2D NMR experiments including 
1
H, 
13
C, 
JMOD, 
1
H-
1
H COSY, HSQC, HMBC and NOESY measurements.  
Iriflophenone 2-O-β-glucopyranoside (CG2): amorphous solid; α]D
25
 28 (c 0.1, MeOH); 
APCI-MS positive m/z 409 [M+H]
+
, 247 [(M+H)C6H10O5]
+
, 153 [C7H5O2+MeOH]
+
, 121 
[C7H5O2]
+
; HRESIMS: m/z 431.0940 [M+Na]
+
 (calcd for C19H20O10Na 431.0954); 
1
H- and 
13
C-NMR data are identical with published data [136].  
Iriflophenone 3-C-β-glucopyranoside (CG3): amorphous powder; APCI-MS m/z 409 
[M+H]
+
, 231, 219, 195; 
1
H NMR (500 MHz, CD3OD)  (ppm): 7.62 (2H, d, J = 8.7 Hz, H-
2’,6’), 6.79 (2H, d, J = 8.7 Hz, H-3’,5’), 5.98 (1H, s, H-5), 4.87 (1H, d, J = 9.6 Hz, H-1”), 
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3.88 (2H, m, H-2”,6a”), 3.75 (1H, dd, J = 12.0, 5.1 Hz, H-6b”), 3.48 (2H, m, H-3”,H-5”), 
3.42 (1H, m, H-4”). 1H-NMR data are in agreement with those published earlier for DMSO-
d6 solution [137]. 
(6aR,11aR)-()-Maackiain (CG8): white powder; [α]D
25
 177 (c 0.1, CHCl3); 
1
H-NMR 
(500 MHz, DMSO-d6)  (ppm): 9.61 (1H, s, OH), 7.23 (1H, d, J = 8.4 Hz, H-1), 6.96 (1H, s, 
H-7), 6.53 (1H, d, J = 1.8 Hz, H-4), 6.52 (1H, s, H-10), 6.46 (1H, dd, J = 8.4, 1.9 Hz, H-2), 
5.94 and 5.91 (2x1H, 2xs, -OCH2O-), 5.50 (1H, d, J = 6.9 Hz, H-11a), 4.22 (1H, dd, J = 10.1, 
3.8, H-6), 3.58 (1H, m, H-6), 3.54 (1H, m, H-6a); 
13
C-NMR (125 MHz, DMSO-d6)  (ppm): 
158.7 (C-3), 156.3 (C-4a), 153.7 (C-10a), 14.4 (C-9), 141.0 (C-8), 132.0 (C-1), 118.4 (C-7a), 
111.3 (C-1a), 109.7 (C-2), 105.3 (C-7), 101.0 (-OCH2O-), 102.8 (C-4), 93.2 (C-10), 77.9 (C-
11a), 65.8 (C-6), 39.0 (C-6a). 
(6aR,11aR)-()-2-Methoxymaackiain (CG7): white powder; [α]D
25
 331 (c 0.1, CHCl3); 
APCI-MS positive m/z 315 [M+H]
+
; 
1
H- and 
13
C-NMR data in CDCl3 were in good 
agreement with literature data [138, 139]. NMR data in DMSO-d6 are reported for the first 
time: 
1
H-NMR (500 MHz, DMSO-d6)  (ppm): 9.30 (1H, s, OH), 6.96 (1H, s, H-1), 6.93 
(1H, s, H-7), 6.53 (1H, s, H-4), 6.32 (1H, s, H-10), 5.49 (1H, d, J = 6.7 Hz, H-11a), 5.94 and 
5.91 (2x1H, 2xs, -OCH2O-), 4.19 (1H, m, H-6), 3.53 (2H, m, H-6, H-6a), 3.74 (3H, s, OCH3);
 
13
C-NMR (125 MHz, DMSO-d6)  (ppm): 153.7 (C-10a), 149.6 (C-4a), 148.2 (C-9), 147.4 
(C-3), 143.0 (C-2), 141.0 (C-8), 118.5 (C-7a), 113.8 (C-1), 110.1 (C-1a), 105.4 (C-7), 103.8 
(C-4), 101.0 (-OCH2O-), 93.2 (C-10), 78.2 (C-11a), 65.9 (C-6), 56.2 (OCH3), 40.0 (C-6a).  
Hesperetin (CG12): APCI-MS positive m/z 303 [M+H]
+
, 176, 153; 
1
H- and 
13
C-NMR data 
were in good agreement with literature data [140], but in DMSO-d6 are reported for the first 
time: 
1
H-NMR (500 MHz, DMSO-d6)  (ppm): 12.10 (1H, brs, OH), 6.93 (1H, d, J = 8.5 Hz, 
H-5’), 6.92 (1H, d, J = 1.7 Hz, H-2’), 6.86 (1H, dd, J = 8.4, 1.7 Hz, H-6’), 5.88 and 5.86 
(2x1H, 2xd, J = 1.9 Hz, H-6, H-8), 5.42 (1H, dd, J = 12.3, 2.9 Hz, H-2), 3.77 (3H, s, OCH3), 
3.18 (1H, dd, J = 17.1, 12.5, H-3a), 2.69 (1H, dd, J = 17.1, 3.0, H-3b); 
13
C-NMR (125 MHz, 
DMSO-d6)  (ppm): 196.0 (C-4), 167.2 (C-7), 163.5 (C-5), 162.8 (C-9), 147.9 (C-4’), 146.5 
(C-3’), 131.2 (C-1’), 117.7 (C-6’), 114.1 (C-5’), 112.0 (C-2’), 101.6 (C-10), 95.9 (C-6), 95.1 
(C-8), 78.2 (C-2), 55.7 (OCH3), 42.1 (C-3). 
The further compounds were identified by comparing of their physical and spectroscopic 
data with reported data as luteolin (CG1) [141, 142], naringenin 5-O-β-glucoside (= 
helichrysin B) (CG4) [143], afrormozin (CG9) [144], formononetin (CG10) [145], 
liquiritigenin (CG11) [137, 140], naringenin (CG13) [137, 140], 5,7,3’,5’-
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tetrahydroxyflavanone (CG14) [142], genistein (CG15) [146], isoliquiritigenin (CG16) [147] 
and diosmetin (CG17) [140]. CG5 was identified as piceol (= 4-hydroxyacetophenone) and 
CG6 as 4-hydroxybenzaldehide based on their 
1
H-, 
13
C-NMR and MS data.  
5.2.3. Oestrogen-like activity  
Recently, the phytoestrogenic potential of extracts from different Cyclopia species was 
reported, as well as some compounds, present in Cyclopia were also tested [6, 65, 72, 74]. 
However bioactivity-guided isolation was reported from C. subternata, but not from 
C. genistoides, which species also displayed significant phytoestrogenic activity in previous 
studies [63, 65]. 
The methanol extracts from fermented and non-fermented C. genistoides were assayed 
with a highly efficient and convenient transgenic plant system, Arabidopsis thaliana 
pER8:GUS line, in order to detect oestrogenic/anti-oestrogenic activity. The transgenic plant 
pER8:GUS, with the GUS gene as a gene fusion marker for the analysis of gene expression, 
can be used to quantify the bioactivity of phytoestrogens [148]. Moreover, it is a visible 
system, primary results can be readily observed visually, without the need of special 
instrumentation. The system contains an oestrogen receptor-based transactivator vector 
(XVE) as an activator unit and the GUS (β-glucuronidase) gene as a reporter [149]. 
The XVE system is an oestrogen receptor-based chemical-inducible system, which was 
developed by Zuo et al. in 2000. It comprises a DNA binding domain of the bacterial 
repressor LexA (X), an acidic transactivating domain of VP16, and the regulation region of 
the ER-α. The XVE activator is strictly regulated by oestradiol; in case of the presence of 
oestrogen active compounds the activator stimulates the expression of GUS transcription 
[149]. GUS protein containing transgenic plants give blue colour, after adding a 
glucopyranosiduronic acid containing dye. 
After the solvent-solvent partition of the methanolic extracts of the fermented and non-
fermented herb of Cyclopia genistoides, the n-hexane, EtOAc, CH2Cl2 and aqueous MeOH 
layers were screened by the transgenic plant pER8:GUS reporter system at 100 and 
200 μg/ml. Oestrogenic activity of the extracts was detected via a histochemical assay for 
GUS activity. The CH2Cl2 and EtOAc layers of the fermented and non-fermented 
C. genistoides were proved to be active, thus were selected for bioactivity-guided 
fractionation, by the means of HPLC, MPLC, VLC, RPC, CC and preparative TLC. From the 
CH2Cl2 fraction of the fermented plant material four out of fourteen subfractions, yielded via 
polyamide column chromatography, exhibited oestrogenic like effects (P8-P11, MAC ≤ 200 
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μg/ml). P8 and P11 contained one, P9 two and P10 three of the isolated compounds with 
oestrogen-like activity. From the EtOAc fraction of the non-fermented C. genistoides four out 
of twelve VLC subfractions were active in the oestrogen-like reporter assay (V2, V3, V6, V7, 
MAC ≤ 200 μg/ml). One, two and two active constituents were found in V7, V2 and V3 
subfractions, respectively.  
Bioassay-directed chromatographic fractionation led to the isolation of six flavonoids with 
oestrogenic activity: CG1, CG4, CG13, CG14, CG15, and CG16, luteolin, helichrysin B 
(naringenin-5-O-β-glucoside), naringenin, 5,7,3’,5’-tetrahydroxyflavanone, genistein and 
isoliquiritigenin, respectively. The compounds were identified by comparing their physical 
and spectroscopic data with reported data and by APCIMS/MS [145, 150-152]. From the 
fractions of the CH2Cl2 layer exhibiting oestrogenic activity, P9 yielded CG13, CG14, 
fraction P10 afforded CG15, CG16 and P11 furnished CG1 (Figure 3). Fractions P8 and P10 
were also analysed by HPLC (Method 2, Instrument 2) and CG13 and CG14 were also 
detected from these fractions, respectively. From the EtOAc layer, the active fractions V2 
and V3 were also chromatographed by HPLC (Method 2, Instrument 2). CG14 was 
detected in both fractions, while CG13 only in V2. The active constituent CG1 and CG4 were 
isolated from active fractions V3 and V7, respectively (Figure 3). 
The least potent compound was helichrysin B with a MAC of 115 μM (Figure 4). Two 
compounds, which have not yet been isolated from C. genistoides, genistein and 
isoliquiritigenin exhibited substantial effect with a MAC of < 11.56 and 12.19 μM. Luteolin, 
naringenin and 5,7,3’,5’-tetrahydroxyflavanone possessed oestrogen-like activity too, with a 
MAC of 87.5, 23.0 and 86.5 μM. The minimum active concentration of the control, E2 was 
found to be 2.5 nM. 
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Figure 4. Oestrogenic MAC of the active isolated compounds in the histochemical assay 
The concentrations where the blue colour was detectable are surrounded with red boxes, indicating oestrogenic activity. The 
last/only concentration where the blue colour was still detectable was considered the minimum active concentration. 
E2: 17-β-oestradiol 
5.2.4. HPLC quantification of compounds with oestrogen-like activity 
The quantitative comparison of the six active compounds between the fermented and non-
fermented C. genistoides was performed by RP-HPLC (Method 2, Instrument 2). Peaks 
were identified by comparison of retention times and UV-Vis spectra (PDA detector) with 
those of the isolated compounds. 
While both the processed and unprocessed plant contained similar amounts of luteolin and 
isoliquiritigenin, the naringenin and 5,7,3’,5’-tetrahydroxyflavanone content in the fermented 
honeybush was more than 30 and 10 fold, respectively (Table 2). On the other hand, the non-
fermented Cyclopia had higher quantities of the naringenin-glycoside, which showed the 
weakest oestrogen-like activity amongst the six active compounds. 
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The quantitative comparison of the extract used for the bioactivity-guided isolation 
(methanolic extract) and the traditionally used aqueous extract (“cup of tea extract”) was also 
performed. The “cup of tea” extracts, prepared with boiling tap water, had much lower 
concentrations of the active compounds. Isoliquiritigenin was below the detection limit in 
aqueous extracts, whereas 5,7,3’,5’-tetrahydroxyflavanone was undetectable in the water 
extract of the non-fermented sample. Genistein was not detected in any of the extracts. 
Table 2. The quantitative determination of the active compounds 
n.d. (not detected), LOD limit of detection, LOQ limit of quantification, values are given in ±SD 
In another experiment the possible effect of the intestinal flora on aqueous extracts of 
fermented and non-fermented C. genistoides using commercially available mixture of 
probiotic bacteria was assessed. Two bioactive constituents (naringenin, luteolin) were 
quantified by HLPC (Instrument 2, Method 2 – with an injection volume of 45 μl) before 
and after bacterial fermentation of the aqueous extracts. While both the processed and 
unprocessed plant contained similar amounts of luteolin, the naringenin content in the 
fermented honeybush was higher. However, after 50 hours of bacterial fermentation most 
likely due to the loss of sugar moiety, the naringenin and luteolin content was approximately 
similar in both the fermented and non-fermented honeybush (Annex 2). The concentration of 
luteolin and naringenin were higher but similar in both processed and unprocessed herbs after 
glycosidic cleavage by bacteria.  
5.2.5. Antiproliferative activity 
Fractions and compounds of Cyclopia extracts, were also reported to be able to induce and/or 
inhibit cell-proliferation, depending on their amount, structure, the ERα/β ratio of the cells, 
the presence of E2, ERα/β antagonism/antagonism or ER-independent antiproliferative effect 
of the compounds and their ratio in an extract [72, 74, 153]. In order to measure the 
Compound MeOH extract Aqueous extract 
LOD 
(μg) 
LOQ 
(μg) 
 Fermented 
(mg/g dried plant 
material) 
Non-fermented  
(mg/g dried plant 
material) 
Fermented 
(mg/g dried plant 
material) 
Non-fermented 
(mg/g dried plant 
material) 
Luteolin 0.0439 ± 0.0062 0.0511 ± 0.0144 0.0152 ± 0.0012 0.0174 ± 0.0062 0.2260 0.7533 
Naringenin 0.1334 ± 0.0122 0.0037 ± 0.0005 0.0391 ± 0.0016 0.0027 ± 0.00003 0.1880 0.6268 
Genistein n.d. n.d. n.d. n.d. 0.2578 0.8594 
Isoliquiritigenin 0.0038 ± 0.0006 0.0026 ± 0.0001 n.d. n.d. 0.3125 1.0416 
5,7,3’,5’-
tetrahydroxy-
flavanone 
0.0842 ± 0.0301 0.0079 ± 0.0024 0.0489 ± 0.0076 n.d. 0.2750 0.9167 
Helichrysin B 0.1623 ± 0.0463 0.2375 ± 0.0930 0.3279 ± 0.0261 0.3376 ± 0.0540 0.3290 1.0967 
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antiproliferative effect of the isolated compounds, antiproliferative testing was conducted on 
T47D (ER positive) and A2780 (ER negative) human cancer cells. 
In Table 3, fractions and compounds with inhibition values above 30% either in A2780 or 
T47D cells are displayed. While in the pER8:GUS assay P8-11, V2, V3, V6, V7 showed 
oestrogenic activity; in the antiproliferative tests, P8, P10, P11 and V3 demonstrated 
inhibition greater than 30% in either cell-lines. Except of helichrysin B and 5,7,3’,5’-
tetrahydroxyflavanone, all compounds with oestrogen-like activity (naringenin, luteolin, 
isoliquiritigenin, genistein) exhibited substantial antiproliferative activity against the tested 
cell lines. All four of them had a greater inhibition towards the ER negative A2780.  
Substance / 
fraction Concentration (µg/ml) Growth inhibition (%) ± SEM 
A2780 T47D 
V3 10 83.83 ± 0.78 50.90 ± 0.98 
30 88.35 ± 0.28 69.95 ± 0.57 
V4 10 –* 11.06 ± 1.20 
30 16.16 ± 2.96 33.76 ± 1.57 
P7 10 – 12.54 ± 2.90 
30 42.83 ± 1.27 40.07 + 1.59 
P8 10 22.27 ± 2.34 40.81 ± 2.38 
30 43.44 ± 1.02 48.73 ± 0.97 
P10 10 26.42 ± 1.97 44.97 ± 2.67 
30 39.90 ± 0.90 50.16 ± 2.29 
P11 10 22.06 ± 2.58 32.90 ± 2.67 
30 51.97 ± 1.01 44.42 ± 1.76 
Luteolin 10 53.43 ± 0.82 37.43 ± 2.35 
30 91.60 ± 0.61 65.10 ± 1.17 
Genistein 10 39.40 ± 1.33 14.98 ± 1.50 
30 84.79 ± 0.59 39.02 ± 1.30 
Naringenin 10 15.95 ± 0.97 – 
30 41.42 ± 2.19 22.64 ± 1.30 
Isoliquiritigenin 10 19.53 ± 1.86 – 
30 71.13 ± 0.64 36.50 ± 2.11 
Table 3. Fractions and compounds exhibiting substantial (above 30%) antiproliferative activity against either A2780 or 
T47D cells. 
*Conditions exerting inhibition less than 10% are considered ineffective and the exact values are not presented for clarity. 
All the presented results are statistically different (p < 0.05) from the untreated control cells. 
5.2.6. Xanthine oxidase inhibitory activity  
Cyclopia species are valuable sources of bioactive compounds, due their content of vast 
range of polyphenolic constituents. They are likely to be responsible for the studied 
oestrogen-like, antimutagen, chemopreventive, pancreatic β-cell protective and antioxidant 
activities [6, 67, 110, 154]. Considering the phytochemistry and bioactivities of Cyclopia 
species, testing the extracts and compounds for xanthine oxidase inhibitory activity seemed 
plausible. 
Both dichloromethane layers derived from the methanolic extract of the fermented and 
non-fermented plant material exerted xanthine oxidase inhibitory activity thus were subjected 
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to further chromatography. The CH2Cl2 layers of the fermented and non-fermented plant 
material were separated into fourteen and twelve fractions by a polyamide column (OCC-P) 
with mixtures of MeOH and H2O as eluents. Fractions PP8 from the non-fermented and P10 
from the fermented herbal substance were amongst the fractions with the strongest inhibition 
of xanthine oxidase (Figure 5). Further purification of these fractions led to the isolation of 
luteolin and diosmetin (CG1 and CG17) exerting remarkable XO inhibitory effect with IC50 
values of 0.84 μM (95% confidence interval 0.80 to 0.91 μM) and 0.53 μM (95% confidence 
interval 0.40 to 0.80 μM), respectively. The inhibitory activity of both compounds 
significantly exceeded that of allopurinol (IC50 = 7.49 ± 0.29 μM), which was used as a 
positive control.  
Alongside with the bioactivity-guided isolation, all other isolated compounds were tested. 
From the 15 already isolated constituents only two structurally close flavanones, hesperetin 
(CG12) and 5,7,3’,5’-tetrahydroxyflavone (CG14) exhibited a weak inhibition (IC50 = 55.20 
μM (95% confidence interval 41.40 to 73.51 μM) and 120.55 μM (95% confidence interval 
101.71 to 142.86 μM), respectively). The rest of the isolated compounds showed no xanthine 
oxidase inhibition (IC50 > 150 μM). 
  
Figure 5. Xanthine oxidase inhibition by the fractions yielded from the CH2Cl2 layers of the fermented (P1-P14) and non-
fermented (PP1-PP12) plant material. ALP - allopurinol. CH2Cl2Ferm - CH2Cl2 layer of the fermented honeybush. 
CH2Cl2NonFerm - CH2Cl2 layer of the non-fermented honeybush.  
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6. DISCUSSION 
6.1. Sympathomimetic activity of H. gordonii 
In the course of the investigation of the mechanism of action of the Hoodia gordonii extract 
containing product, it showed a propranolol-sensitive and concentration-dependent relaxation 
of uterine rings, against both spontaneous and stimulated contractions. Hence a 
sympathomimetic effect with substantial β-receptor-mediated contribution is proposed. The 
results support the cardiovascular side effects reported in a human clinical trial [98]. 
The gestation-dependent myometrial effect (weaker relaxing effect on uteri from late-
pregnant animals) of substances acting on the sympathetic system could be explained by the 
changes in the receptor function during pregnancy. The nonpregnant uterus of the rat exhibits 
limited α-adrenoceptor-mediated contraction but efficiently relaxed by β-adrenergic 
stimulation. Late-pregnant myometrium is sensitive to both α- and β-adrenergic stimulation, 
and therefore, the overall response is determined by the receptor preference of the tested 
substance [135]. It is plausible that the limited relaxation of late-pregnant myometrium, 
induced by the product, is a consequence of a balanced α- and β-adrenoceptor stimulation 
that can be shifted towards increased contractility by masking the action, mediated through β-
receptors.  
The Hoodia product contained alcohol, and since ethanol may alter β-adrenergic receptor 
binding affinity [155], the sample of Hoodia spray was evaporated to dryness, and then the 
residue was dissolved to the original volume with physiological saline - DMSO (95:5). Since 
the tested Hoodia commercial product possesses sympathomimetic effects, its use may cause 
both appetite suppression and increased thermogenesis, resulting in weight loss [156, 157]. 
Moreover, in the experiments performed in the US patent application, increased water 
consumption was recorded during feeding studies, which is a well-known effect of 
sympathomimetic agents. The side effects (increase in blood pressure, pulse, heart rate), 
reported in the human clinical trial, is also in line with a possible sympathomimetic action 
[98].  
Chemical composition of Hoodia has not been fully mapped yet. The investigations 
performed with H. gordonii primarily focussed on the pregnane glycosides; however, other 
potentially active constituents with sympathomimetic activity may also be present in the 
plant. 
In an animal study a H. gordonii commercial dried extract interacted with the 
noradrenergic, dopaminergic and serotonergic systems [106]. Although, this study examined 
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the anti-depressant effect of Hoodia, the mechanism of action showed similarity with other 
anti-obesity drugs; for example, a popular combination of two weight loss medication 
fenfluramin and phentermin (fen-phen), acting on the noradrenergic and serotonergic 
signaling pathways. However, fen-phen, was withdrawn due to its association with cardiac 
valvular heart disease and pulmonary hypertension [158]. Sympathomimetic agents as 
amphetamine derivatives or sibutramine are effective in weight management, but they pose 
serious risk to public health due to their serious cardiovascular side effects. In the case of 
H. gordonii, cardiovascular side effects and proposed anorectic property are reported, raising 
the questions whether these effects are caused by the same constituents; and if they are, 
whether the responsible compound is truly P57. Our results are indicating that Hoodia acts 
similarily to amphetamine derivates, thus if a Hoodia product consumption results in weight-
loss, the reported side effects most likely will manifest. Hence, the inclusion of Hoodia 
species to the food-supplement area may be dangerous. 
6.2. Structure elucidation 
Fractionation (mainly bioactivity-guided) of Cyclopia genistoides led to the isolation of 17 
compounds from which fourteen were first isolated from this species, ten from the genus.  
The isolated compounds are amorphous solids or crystals. The structures of the isolated 
compounds were elucidated by means of spectroscopic methods. From HRESIMS 
measurements, the molecular compositions were determined. The most useful data 
concerning the chemical structures were furnished by 1D and 2D NMR spectroscopy.  
Multistep chromatographic separation and purification procedure, including CC, VLC, 
RPC, PLC, MPLC and HPLC, resulted in the isolation of pure compounds CG1-17. CG2 and 
CG3 were identified as benzophenone derivatives based on their spectral characteristics. 
CG2 was identified as iriflophenone 2-O-β-glucopyranoside by comparing its spectral data 
with those reported in the literature [136]. CG3 proved to be identical with iriflophenone 3-
C-β-glucopyranoside, isolated earlier from C. genistoides [70], and C. subternata [159]. 
CG7 and CG8 were found to have a pterocarpan nucleus, substituted with 
methylenedioxy, hydroxy and methoxy groups. After detailed MS and NMR studies CG8 
could be identified as (6aR,11aR)-()-maackiain [160] and CG7 as (6aR,11aR)-()-2-
methoxymaackiain [138, 139]. Two-dimensional NMR investigations, including 
1
H-
1
H 
COSY, NOESY, HSQC and HMBC experiments, permitted unpublished 
1
H and 
13
C 
assignments for both compounds. This is the first isolation of 2-methoxymaackiain (CG7) 
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and maackiain (CG8) from the Cyclopia genus; previously these compounds were published 
only from Ulex and other Fabaceae species [161-163].  
Fourteen compounds [(iriflophenone 2-O-β-glucopyranoside (CG2), helichrysin B (CG4), 
piceol (CG5), 4-hydroxybenzaldehid (CG6), ()-2-methoxymaackiain (CG7), ()-maackiain 
(CG8), afrormozin (CG9), formononetin (CG10), liquiritigenin (CG11), naringenin (CG13), 
5,7,3’,5’-tetrahydroxyflavanone (CG14), genistein (CG15), isoliquiritigenin (CG16), 
diosmetin (CG17)] were first isolated from the species and ten [iriflophenone 2-O-β-
glucopyranoside (CG2), helichrysin B (CG4), piceol (CG5), 4-hydroxybenzaldehid (CG6), 
()-2-methoxymaackiain (CG7), ()-maackiain (CG8), liquiritigenin (CG11), 5,7,3’,5’-
tetrahydroxyflavanone (CG14), genistein (CG15) and isoliquiritigenin (CG16)] from the 
genus Cyclopia. 
6.3. Oestrogen-like activity of C. genistoides 
There are plenty available methods for the investigation of oestrogenic potential, yet the 
complexity of the mechanisms of action of phytoestrogens and phytoestrogen containing 
herbal preparations triggers divergent outcomes, depending on the method used. The cost-
effectiveness, tolerance toward higher doses of cytotoxic compounds, the ability to detect 
both ER agonists and antagonists and high efficiency and versatility made pER8:GUS an 
ideal screening system for the preliminary investigation of plants with proposed oestrogen-
like activities. Furthermore, while cytotoxicity is a limiting factor of in vitro mammalian cell-
based models, the transgenic plant system expressed tolerance towards higher doses of 
cytotoxic compounds [164]. pER8:GUS cannot distinguish between ER agonists and 
antagonists, however, theoretically it may be possible, if the test compounds are administered 
together with E2. Limitations of this transgenic plant assay may be its relative lower 
sensitivity and that it only determines ER-α interactions. However, phytoestrogens usually 
bind both ER-α and ER-β (with higher affinity towards ER-β), hence this model is suitable 
for natural product screening [148, 149, 165, 166]. 
Mainly, the pharmacological studies, testing phytoestrogenic potential of Cyclopia species 
have focused on different extracts. Bioactivity-guided isolation made it possible to identify 
six compounds responsible for the action, four of them first reported in the genus Cyclopia. 
Interestingly naringenin was present in the plant in high quantities, despite the fact that in two 
studies it was declared absent according to HPLC determination [65, 72]. Genistein – usually 
used as positive reference in phytoestrogenic studies – was also found in the herbal 
substance. During the later preparative work, further well-known phytoestrogens were 
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isolated from the CH2Cl2 layer of the methanolic extract of the fermented plant material: 
diosmetin, afrormosin, liquiritigenin (a selective ER-β antagonist) and formononetin 
(reported higher affinity towards ER-β) [72, 167, 168]. Hesperetin was also isolated, which 
was reported to be one of the most potent natural aromatase inhibitors [169]. Luteolin, 
genistein, isoliquiritigenin and naringenin are widely known phytoestrogens. Naringenin, 
luteolin and genistein were able to displace 70%, 92% and 95% of the [
3
H]-E2 from hERβ, 
respectively, exerting the highest displacements when 10 phytoestrogens were compared 
[65]. Phytoestrogens have the potential to maintain bone health and delay or prevent 
osteoporosis, one of the postmenopausal symptoms. Genistein (54 mg/day) was found to 
have positive effects on bone mineral density on osteopenic postmenopausal women [170]. 
Isoliquiritigenin is also a promising agent for bone destructive diseases [171]. Next to their 
effect on the bone they also possess other activities, potentially important in the treatment of 
postmenopausal symptoms. Genistein and luteolin in vitro suppressed the induction of the 
proliferation-stimulating activity of environmental oestrogens, suggesting anti-estrogenic and 
anti-cancer effect [172]; and naringenin attenuated many of the metabolic disturbances 
associated with ovariectomy in female mice [173]. Genistein was also associated with 
favourable effects on both glycaemic control and some cardiovascular risk markers in 
postmenopausal women [174]. Regular grapefruit juice (contains high amounts of 
naringenin) consumption by middle-aged, healthy postmenopausal women was found to be 
beneficial for arterial stiffness [175]. 
The presence of these phytoestrogens gives a rationale to the traditional use of honeybush 
tea. Although, in the literature different extracts from different Cyclopia species exerted 
varying phytoestrogenic activity, even between harvestings, questioning the real potential of 
medicinal use of honeybush [65, 72-74]. 
6.4. HPLC quantification of compounds with oestrogen-like activity 
The effect of the fermentation on honeybush tea and the plausibility of the tradition of 
fermentation was an interesting aspect to explore. Fermentation reduces the total phenolic 
content, yet traditionally the fermented tea is consumed. It is also important to note that it 
was shown that the total phenolic content of C. genistoides - the first Cyclopia species to be 
used as tea - was the least affected by fermentation (77% retention) when compared to the 
other three, commercially important Cyclopia species [67]. The degradation of flavonoid-
glycosides during the fermentation process could explain the difference in the measured 
amounts of the active compounds between the samples. From the six compounds with 
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oestrogen-like activity, three differed in quantity between the fermented and non-fermented 
herbs. Compounds more abundant in the fermented plant material (5,7,3’,5’-
tetrahydroxyflavanone, naringenin) displayed stronger oestrogen-like activity than 
helichrysin B (higher quantities in the non-fermented honeybush) providing a rationale to the 
fermentation process.  
On one hand, although our experiments reported potent and well-known phytoestrogens to 
be comprised by C. genistoides and the HPLC quantification underpinned the possible 
importance of fermentation process, the low concentrations of the tested compounds are 
questioning the potential phytoestrogenic activity of the traditionally used infusion of 
honeybush. Oestrogenic isoflavones, such as formononetin and calycosin shown to be present 
in another Cyclopia species, C. subternata, but they were also not observed in quantifiable 
amounts [6]. Furthermore, in the literature, different extracts from different Cyclopia species 
exerted varying phytoestrogenic activity, even between harvestings, adding to the debate of 
the real potential of the infusion in medicinal use.  
On the other hand, according to Verhoog et al. the aqueous extracts of non-fermented or 
fermented C. genistoides and C. subternata were able to significantly displace 1 nM [
3
H]-E2 
from hERβ. Although, this effect was not observed in all tested harvestings, it did show the 
possibility of an aqueous extract to be oestrogenic. It also has to be taken into account, that 
although the isolated flavonoids are present in small quantities, the oestrogenic activity of 
Cyclopia extracts is the result of a fine balance between different polyphenols present in 
varying amounts with varying phytoestrogenic potential. A good example is a recently 
performed study, where the activity guided fractionation of an extract from C. subternata, 
which displayed three desirable oestrogenic attributes, showed, that the retention of all these 
attributes in one fraction is not an attainable goal [63]. 
Although, the HPLC quantification underpinned the tradition of fermentation, but taking 
into account the conversion of polyphenolic glycosides by intestinal flora, eventually the 
difference between the two forms of honeybush may not be substantial. The traditional 
fermentation process (high temperature oxidation) reduces the total polyphenolic content of 
Cyclopia spp., but according to our results, bacterial fermentation may increase the content of 
aglycones, which usually possess more pronounced bioactivities than their corresponding 
glycosides, and their bioavailability is remarkably higher than those of the respective 
glycosides [67, 176-180]. 
The naringenin and luteolin content was measured in processed and unprocessed 
C. genistoides, before and after bacterial fermentation. Both bioactive aglycones are present 
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in the plant alongside with their glycosides, making them perfect candidates for studying 
glycosidic cleavage. While the naringenin content was higher in the traditionally used, 
processed plant material, the bacterial fermentation equalised this difference. Hence, the 
difference in the concentration of other bioactive aglycones between processed and 
unprocessed herbal substance may also decrease or disappear after bacterial fermentation. 
However, it has to be noted, that several studies on the phenolic composition of honeybush 
have demonstrated that large variation exists between different batches of plant material from 
the same plantation. Hence, a direct comparison of the processed and unprocessed 
C. genistoides would be more ideal when the plant material is processed on lab-scale and not 
on factory-scale, which could not been performed in our study. 
In our experiment the concentration of luteolin and naringenin were higher in both 
processed and unprocessed herbs after glycosidic cleavage by bacteria, which is important 
regarding, that glycosides cannot be absorbed in their native form in the small intestine, but 
must be hydrolysed by before absorption [178]. In unprocessed plant materials glycosides are 
usually present in higher quantities. For example, soybean contains negligible amounts of 
isoflavone aglycones unless it is fermented [177]. 
The majority of the commercially available honeybush teas are fermented products, 
similar to the traditionally consumed teas, however, recently the non-fermented form has also 
been commercialised. In some advertisements it is claimed that e.g. “the unfermented 
“green” honeybush is also popular and contains even more anti-oxidants” [181]. This notion 
may be based on in vitro experiments, where the traditional fermentation process reduced the 
total polyphenol content and consequently the antioxidant activity of honeybush [67]. 
However, taking into account the conversion of polyphenolic glycosides by intestinal flora, 
the difference between the two forms of honeybush practically may not be substantial. 
6.5. Antiproliferative activity of C. genistoides 
In the MTT assay, naringenin, luteolin, isoliquiritigenin and genistein exhibited substantial 
antiproliferative activity against the tested cell lines. All four of them had a greater inhibition 
towards the ER negative A2780 cell line, which may suggest an ER-independent inhibition of 
cell proliferation, or possibly the induction of cell proliferation in the ER positive T47D 
cell line; underlining their oestrogenic potential. The well-documented ER-mediated actions 
of these flavonoids cannot be excluded as a component of their antiproliferative properties. 
However, in our current experimental conditions the cell culture medium contained a 
substantial amount of natural oestrogens, as components of foetal bovine serum, and 
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therefore the obtained results do not support a direct relationship between the two determined 
activities. 
6.6. Xanthine oxidase inhibitory activity of Cyclopia genistoides 
Gout is the most prevalent form of inflammatory arthropathy with the precondition of 
elevated serum urate levels; thus urate-lowering xanthine oxidase inhibitors are the 
cornerstones of a successful long-term gout management [182]. The first-line treatment in the 
urate-lowering therapy (ULT) of gout is the xanthine oxidase inhibitor allopurinol, which 
needs to be gradually increased to achieve the therapeutic target, and one of its adverse 
reactions is the rare but potentially lethal allopurinol hypersensitivity syndrome. Of the two 
agents available for ULT, febuxostat is more expensive which may in part limit its use, and 
rarely associated with hypersensitivity vasculitis. Hence new xanthine oxidase inhibitors are 
needed in gout therapy, but beside gout, hyperuricaemia may also be an independent risk 
factor in cardiovascular and renal diseases, which underlines the importance of this class of 
compounds [183]. 
The bioactivity-guided isolation of the fermented and non-fermented plant materials led to 
the isolation of diosmetin and luteolin with an inhibitory activity exceeding that of 
allopurinol, currently used in therapy. 
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7. SUMMARY 
H. gordonii and C. genistoides attracted considerable interest because of their potential 
therapeutic use. 
Although, previous pharmacological studies have shown that H. gordonii could have 
different mechanism of action than the already withdrawn sympathomimetic medicines, thus 
a possibly better risk/benefit ratio than the former antiobesity drugs. Yet, our research 
indicated otherwise. The recorded sympathomimetic effect with substantial β-receptor-
mediated contribution is similar to the mechanism of action of several already withdrawn 
weight loss medications. As this result is in accordance with the reported side effects, the use 
of Hoodia gordonii as a possible anti-obesity drug is questionable. 
We linked the phytoestrogenic activity of C. genistoides extracts to compounds, isolated 
via bioactivity-guided fractionation, using the transgenic plant system pER8:GUS. The 
extracts of the plant materials were subjected to multiple step chromatographic separation 
(including CC, VLC, MPLC, HPLC, PLC, RPC) resulting in the isolation of 17 compounds 
from which 14 were first isolated from this species and 10 from the genus. 
Antiproliferative MTT assays were also performed on A2780 and T47D human cancer 
cell lines. The results suggested, that oestrogen induced cell-proliferation or oestrogen 
independent antiproliferative effect might have played a role. 
The recorded xanthine oxidase inhibitory activity of two compounds isolated from the 
dichloromethane layers, added to the long list of bioactivities of Cyclopia species. 
The effect of fermentation on the phytochemical content was also investigated with the 
means of HPLC. The results supported the tradition, as the fermented honeybush tea was rich 
in compounds with stronger phytoestrogenic activity, while the non-fermented tea contained 
larger amounts from the less active glycoside. However, bacterial fermentation levelled the 
difference in the concentration of naringenin between the aqueous extracts from fermented 
and non-fermented plant materials. 
Although, the quantitative comparison of fermented and non-fermented honeybush 
implies, that the fermented tea has higher amount of these phytoestrogens except the least 
active compound, the measured low amounts question the biological activity of the 
traditionally used infusion. However, it does not exclude the possibility that synergism or 
antagonism of multiple polyphenols targeting different ER isoforms can result in 
phytoestrogenic effect of different extracts, even if the individual compounds are small in 
quantity.  
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Annex 1. Isolated compounds from Cyclopia genistoides 
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Annex 2. Naringenin and luteolin content of fermented and non-fermented 
Cyclopia genistoides before and after 50 hours of bacterial fermentation 
 Luteolin mg/gram Naringenin mg/gram 
0 hour 50 hours 0 hour 50 hours 
Fermented plant material 0.0092 ± 0.006 0.0101 ± 0.0008 0.0233 ± 0.0012 0.0243 ± 0.0002 
Non-fermented plant material 0.0081 ± 0.0006 0.0111 ± 0.0007 0.0185 ± 0.0004 0.0254 ± 0.0001 
  
  
APPENDICES 
The thesis is based on the following publications: 
I. Roza O, Lovász N, Zupkó I, Hohmann J, Csupor D 
Sympathomimetic activity of a Hoodia gordonii product: a possible mechanism of 
cardiovascular side effects 
Biomed Res Int 2013; Paper ID 171059: 6 pages 
II. Roza O, Lai W-C, Zupkó I, Hohmann J, Eloff JN, Chang F-R, Csupor D 
Bioactivity-guided isolation of phytoestrogenic compounds from Cyclopia genistoides 
by pER8:GUS reporter system 
South African Journal of Botany 2016; In Press. 
III. Roza O, Martins A, Hohmann J, Lai W-C, Eloff JN, Chang F-R, Csupor D 
Flavonoids from Cyclopia genistoides and their xanthine oxidase activity 
Planta Medica 2016; 82:1274-1278. 
 
